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Abstract
The prognosis for lung cancer patients remains poor. Five year survival rates have
been reported to be 15%. Studies have shown that dose escalation to the tumor can lead to
better local control and subsequently better overall survival. However, dose to lung tumor
is limited by normal tissue toxicity. The most prevalent thoracic toxicity is radiation
pneumonitis. In order to determine a safe dose that can be delivered to the healthy lung,
researchers have turned to mathematical models predicting the rate of radiation
pneumonitis. However, these models rely on simple metrics based on the dose-volume
histogram and are not yet accurate enough to be used for dose escalation trials. The
purpose of this work was to improve the fit of predictive risk models for radiation
pneumonitis and to show the dosimetric benefit of using the models to guide patient
treatment planning.
The study was divided into 3 specific aims. The first two specifics aims were
focused on improving the fit of the predictive model. In Specific Aim 1 we incorporated
information about the spatial location of the lung dose distribution into a predictive
model. In Specific Aim 2 we incorporated ventilation-based functional information into a
predictive pneumonitis model. In the third specific aim a proof of principle virtual
simulation was performed where a model-determined limit was used to scale the
prescription dose.
The data showed that for our patient cohort, the fit of the model to the data was
not improved by incorporating spatial information. Although we were not able to achieve
a significant improvement in model fit using pre-treatment ventilation, we show some
promising results indicating that ventilation imaging can provide useful information about
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lung function in lung cancer patients. The virtual simulation trial demonstrated that using
a personalized lung dose limit derived from a predictive model will result in a different
prescription than what was achieved with the clinically used plan; thus demonstrating the
utility of a normal tissue toxicity model in personalizing the prescription dose.
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Introduction
Statement of Problem
The prognosis for lung cancer remains poor. Out of 1,529,560 new cancer cases in
2010, 240,610 (15.7%) of those were lung cancers. The situation is further exacerbated by
the poor prognosis for lung cancer patients. Lung cancer accounts for 29% of all cancer
related deaths in men and 26% of all cancer related deaths in women. The 5 year survival
rate for lung cancer has been reported to be 15% (1).
Several promising studies have shown that dose escalation to the tumor can lead
to better local control and subsequently overall survival for non-small-cell lung cancer
(NSCLC) patients (2-5). However, the dose to the tumor is limited by normal tissue
radiation toxicity. For NSCLC patients, the most prevalent toxicity is radiation
pneumonitis. Radiation pneumonitis occurs roughly in 10-20% of all radiation treatments
of NSCLC (6) and usually manifests 1 to 6 months after the completion of radiation
therapy. Symptoms of radiation pneumonitis can include cough, fever, shortness of
breath, and if left untreated radiation pneumonitis can be lethal.
In order to determine a safe dose that can be delivered to the healthy lung tissue,
clinicians and researchers have turned to mathematical models predicting the rate of
radiation pneumonitis. The models describe a probability of developing radiation
pneumonitis as a function of simple dose-volume metrics derived from the dose volume
histogram (DVH). Researchers have also attempted to incorporate patient and clinical
factors into predictive risk models (6, 7). However, the data remains inconclusive and
inconsistent. As a result, the models and therefore physicians rely mostly on population
based dose-volume metrics to design and evaluate thoracic radiation treatment plans.
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Better outcomes for lung cancer patients receiving radiation therapy strongly
depend on treatment personalization. Treatment personalization can only be made
possible by more reliable and accurate radiation pneumonitis dose response models.
Therefore, the purpose of this study will be to improve the accuracy of predictive risk
models for radiation pneumonitis and to show the dosimetric benefit of using the models
to guide patient treatment planning.
Current state of radiation therapy in lung cancer
The survival rates for lung cancer remain poor. There are many reasons for the
poor outcome for lung cancer patients. In many instances, physical symptoms may not be
present at the time of initial diagnosis. In fact, up to 75% of patients that present with
lung cancer have lesions that are unresectable due to the advanced stage of the disease or
systematic spread (8). When surgery is not indicated, either because of the advanced stage
of the tumor or because the patient is unable to tolerate surgery, a combination of
radiation and chemotherapy is used. The exact treatment combination is dependent on the
type and clinical staging of the disease. More than 80% of all lung cancers in the United
States are NSCLC (1). For early stage NSCLC, surgery is often the treatment of choice
with post-operative radiation therapy recommended if there is evidence of microscopic
spread. Patients who are unable to tolerate surgery or who present with locally advanced
NSCLC (defined as stage IIB-IIIB) are treated with a combination of radiation therapy
and concurrent chemotherapy. Overall, approximately 75% of all lung cancer patients in
our clinic receive radiation therapy.
Although technological developments have enabled radiation therapy to deliver
higher doses to the tumor, the biggest reason for death, for patients receiving radiation
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therapy, remains local recurrence of the disease (9-11). Local recurrence can be defined
as failure to eradicate the local disease. If the local disease is not controlled, it can
subsequently lead to metastatic spread (12). Local control can be as low as 15% for
patients who receive standard radiation doses of 66 Gy (13). Studies suggest that an
improved local control rate can lead to a significant improvement in overall survival (2).
Improved outcome shown with dose escalation
Currently, the common clinical practice for thoracic radiation therapy is to deliver
anywhere from 60-66 Gy to the target in either 1.8 or 2 Gy fractions. Several studies have
proposed that one way to increase local control and subsequently overall survival is to
escalate the dose to the tumor. As early as 1987, Perez et al (14) performed a study where
they randomized patients to four different arms that delivered varying doses of radiation
and found that higher doses of radiation were needed to improve tumor control. In
another study, Willner et al (15) retrospectively analyzed 135 NSCLC patients who were
treated to radiation doses ranging from 30 to 80 Gy. They found that there was a clear
dose effect on local control and overall survival. In more recent work, Kong et al. (4)
analyzed a dose escalation trial in which NSCLC patients were treated to doses ranging
from 63-103 Gy in 2.1 Gy fractions using three-dimensional conformal radiation therapy
(3D-CRT). They found that the 5 year control rate was 12%, 35%, and 49%, for patients
treated to doses of 63-69, 74-84, and 92-103 Gy, respectively. They concluded that higher
doses of radiation were associated with improved outcomes. In another dose escalation
trial, Bradley et al. (16) studied 177 patient with inoperable NSCLC. They found that
local control rates of 50-78% were achieved with increasing radiation doses. There are
currently undergoing multi-institutional studies and protocols to evaluate the possibility
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of escalating the dose to the tumor for lung cancer patients (17). Bradley et al (17) report
in their initial findings that that the maximum tolerated dose was 74 Gy in 2 Gy fractions
with three 3D-CRT and concurrent chemotherapy. The 74 Gy dose level was found to be
well tolerated by patients and found to have low rates of radiation pneumonitis.
Dose escalation limited by normal tissue toxicity
Although increasing the radiation dose to the target has been shown to improve
overall survival; it is impossible to increase the dose to the tumor without increasing the
dose to the surrounding healthy tissue. Therefore, the doses that can be delivered to the
target are limited by normal tissue toxicities. The two most common toxicities observed
in thoracic radiation are acute esophagitis and radiation pneumonitis; with radiation
pneumonitis being the more prevalent. Radiation pneumonitis is an acute toxicity that
develops within several weeks or months after radiation therapy. Symptoms of radiation
pneumonitis include dry cough, low grade fever, shortness of breath, chest pain, and if
left untreated radiation pneumonitis can be lethal (7). Treatment for radiation pneumonitis
usually consists of steroids, oxygen, or assisted ventilation depending on the severity of
the condition.
In order to establish a common classification system, clinicians have tried to
establish an objective endpoint that could be used to classify the severity of radiation
pneumonitis. One suggestion has been to classify radiation pneumonitis based on
dyspnea, which is defined as shortness of breath. The difficulty with dyspnea as an
effective end-point is that the condition is non-specific and can be caused by various
other medical conditions (such as infection and cardiac arrhythmia) not related to the
radiation treatment (6). Most current radiation pneumonitis grading systems rely on
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medical intervention. One of the most common scoring systems called the Common
Terminology Criteria for Adverse Events (CTCAE) (18) has been proposed by the
National Cancer Institute. The scoring system (Table 1) consists of severity grades 1
through 5, ranging from asymptomatic (grade 1) to death due to radiation pneumonitis
(grade 5). The most common clinic endpoint used for analysis is grade 3, which is defined
as severe symptoms, oxygen indicated, and limited self care in activities of daily living. It
should be noted that there are different versions of the CTCAE criteria and several
different groups have defined their own criteria for radiation toxicity. The different
radiation

pneumonitis

scoring

systems complicate the analysis of
data from different groups and
institutions. Tucker et al. (19)
explored the impact of the scoring
system on the relationship between
radiation dose and pneumonitis.
Their

data

demonstrated

the

importance of documenting the
criteria

for

pneumonitis.

defining

radiation
Table 1: CTCAE version 3.0 scoring criteria for
radiation pneumonitis.

The range of symptomatic radiation pneumonitis has been reported to be
anywhere from 5 to 50% (6). Some specific examples include a severe pneumonitis rate
of 32% in a cohort of 223 patients treated at MD Anderson Cancer Center (20) and a
pneumonitis rate of 14% from pooled data reported by Kwa et al. (21). However, it

6
should be noted that with newer data that includes newer treatment modalities such as
IMRT, the pneumonitis rate has been reported to be lower. For example, Sura et al. (22)
report a pneumonitis rate of 11% for patients treated with IMRT. Overall, with current
radiation therapy methods, the risk of severe radiation pneumonitis is considered to be
about 10-20%.
Use of risk models to predict for radiation pneumonitis
In order to try to predict a safe dose that can be given to the lung, researchers and
clinicians have turned to predictive mathematical modeling. Mathematical models have
been developed to calculate a normal tissue complication probability (NTCP) for
radiation pneumonitis. One of the earliest models was developed by Lyman (20). The
Lyman model is based on the assumption that the tolerance to radiation dose can be
thought of as a normal distribution. Dose dependence can then be described as the
integral of the normal distribution which produces a sigmoid curve. Mathematically, the
Lyman model can be written as
,

Equation 1

where
Equation 2

Deff is the effective dose, V is the volume, and m, n, and TD50 are model fitting
parameters. The TD50 is the dose corresponding to 50% incidence of the radiation
pneumonitis, m is related to the inverse of the slope of the sigmoid curve, and n is the
volume parameter. A steeper slope (smaller m) indicates that there is more of a dose
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response and that the binary data are separated well, while a smaller slope indicates a flat
curve and a smaller dose response. The volume parameter (n) is a characteristic of the
tissue and is closer to 1 when an organ is considered to be a “parallel” organ and closer to
0 when the organ is considered to be a “serial” organ. The lung is considered to be a
volume organ and therefore most studies suggest that the value of n is closer to 1 (6). The
effective dose (Deff) is the dose-volume metric used as the input into the NTCP model.
The physical meaning of the effective dose is dependent on the definition used to describe
Deff. One common way to calculate the effective dose from the DVH was proposed by
Mohan et al (23). The group proposed that the effective dose can be calculated with
,

Equation 3

where i loops over all the dose bins, v is the relative volume, and D is the dose. Equation
3 is meant to reduce the heterogeneous dose distribution into a uniform dose given to a
volume. With the n parameter set equal to 1 (as is the case in the lung) the effective dose
gets reduced to the mean dose or in the case of lung, the mean lung dose (MLD). Using
the DVH reduction scheme proposed by Mohan et al. (23) the expression in Equation 2
can be re-written as

.

Equation 4

The expressions in Equations 1 and 4 are commonly called the Lyman-Kutcher-Burman
(LKB) formulation of NTCP (24) which is the most widely used complication probability
model in the literature (6). Throughout this work we will use the LKB formulation of
NTCP described in Equations 1 and 4.
It is important to note that there are other mathematical models that describe
NTCP. One class of models uses other mathematical expressions to described a sigmoid
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curve. Examples include the logistic and log-logistic models (25). A study by
Seppenwoolde et al. (26) compared different sigmoid models and determined that the
MLD formulation of the LKB model was the most accurate predictor of radiation
pneumonitis. Another class of models is known as mechanistic models and tries to
describe the biological phenomenon of radiation damage. One example of such a model is
the “cluster” model proposed by Thames et al. (27). Other mechanistic models have been
described that rely on the volume dependence (serial versus parallel) of a tissue (28).
Finally, there are models that select several dosimetric features, instead of a single dosevolume metric, to be included in prediction for radiation pneumonitis (28).
The model parameters (for example m and TD50) are fit to a patient dataset using
maximum likelihood analysis (29). Maximum likelihood analysis is a method of
estimating parameters of a statistical model for binary observations. The likelihood metric
can be described by

,

Equation 5

where i is the number of observations, y is the observation, and p is the probability of the
observation. In terms of toxicity, i is the number of patients, y is the binary observation of
whether or not the patient developed severe pneumonitis (yes or no), and p is equivalent
to the NTCP. Substituting and re-arranging terms, the likelihood equation can be written
as

.

Equation 6

For numerical reasons, the natural logarithm is taken of both sides of Equation 6 and the
log-likelihood is computed. Finally, an optimization algorithm can be used to determine
the model parameters (for example m and TD50) that maximize the log-likelihood. In
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practice, often the negative of the log-likelihood is taken because algorithms may have
routines for determining the minimum rather than the maximum.
In order to perform a complete statistical analysis, it is often desirable to obtain
95% confidence limits on the fitting parameters. For a certain fitting parameter, the 95%
confidence interval is determined by systematically varying the value of that particular
fitting parameter, and optimizing the other parameters to calculate the maximum loglikelihood. The lower and upper 95% confidence intervals are the value of the
optimization parameter that equate to a log-likelihood reduction of 1.92. The value of
1.92 is determined by taking half of the chi-squared distribution that equates to a
significance level of 0.05. The shape of a log-likelihood curve as a function of one
parameter is shown in Figure 1. It should be noted that the shape of the curve is not
symmetric.
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Figure 1: A curve showing the negative log-likelihood as a function of TD50. The curve
graphically illustrates how 95% confidence intervals are determined and the non
symmetric shape of log-likelihood plot.

Factors affecting the risk of radiation pneumonitis
As indicated in Equations 2-4, the two parameters most associated with the
probability of developing radiation pneumonitis are dose and volume (6, 20, 30-33).
Specifically, researchers have discussed metrics such as MLD and the volume receiving
dose greater than a threshold (Vdose) value. For example, Wang et al (20) and Martel et al
(31) found that patients with a higher MLD had a higher incidence of radiation
pneumonitis. Wang et al (20) retrospectively analyzed 223 patients treated with definitive
radiation therapy and concurrent chemotherapy. Using univariate analyses, they found
that MLD was significantly associated with the risk of developing radiation pneumonitis.
Martel et al (31) retrospectively analyzed the DVHs of 64 patients who had their normal
lungs irradiated with 3D-CRT. They reported that patients who had radiation pneumonitis
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had a greater MLD than patients who did not develop radiation pneumonitis. Other
studies, such as those by Yorke et al (34) and Graham et al (30) concluded that the rate of
radiation pneumonitis was significantly correlated to V20. Graham et al (30) analyzed the
dose volume data for 99 patients treated definitively for NSCLC and reported that V20
was significantly associated with the probability of developing radiation pneumonitis.
Yorke et al (34) used 78 patients from a Phase I dose escalation study and reported that
ipsilateral lung V20 was amongst one of the significant variables correlated with radiation
pneumonitis. It is important to note that the literature also suggests that within individual
datasets the dose-volume parameters are often correlated with one another (6, 20, 34).
In addition to dose-volume parameters, researchers have attempted to identify
clinical and patient factors that could help predict for the rate of radiation pneumonitis.
Some of the factors include: the use of chemotherapy (35), performance status (36),
smoking status (37), genetic information (38), tumor location within the lung (32, 33, 39),
and functional status of the lung (40-42). In the lung literature survey, Marks et al (6)
report inconclusive results relating the risk of radiation pneumonitis and surgery. Another
controversial treatment factor that has been investigated is the use of chemotherapy.
Many chemotherapy agents are known to cause pulmonary toxicities and perhaps
exacerbate radiation induced lung injury.

In fact, from clinical experience, many

physicians believe that chemotherapy increases the chance of developing radiation
pneumonitis. However, this result has not been proven in the literature. For example,
Graham et al (30), in their univariate analyses, did not find the use of chemotherapy to be
significantly associated with the risk of developing radiation pneumonitis. Similarly,
Robnette et al (36) did not find the use of chemotherapy to be predictive of radiation
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pneumonitis. In the same study, Robnette et al (36) did find a correlation between
performance status and radiation pneumonitis. Yuan et al (38) reported that certain
genotypes were associated with a lower risk of radiation pneumonitis in NSCLC patients.
Tumor location within the lung has also been studied as a potential factor associated with
radiation pneumonitis. Hope et al (33) found that inferior tumor position was highly
correlated with pneumonitis events while Robnette et al (36) did not find a similar
pattern. Several studies have suggested that incorporating lung function into predictive
models can improve the ability to predict for radiation pneumonitis (42). However, these
are largely methodology and proof of concept studies (43). Overall many patient and
clinical factors have been investigated in an attempt to improve the predictive power of
radiation pneumonitis dose response models; however, the literature remains inconsistent
and inconclusive (6, 7).
Dose escalation trials using mathematical radiation pneumonitis models
Several groups have used predictive mathematical models to guide dose escalation
trials for NSCLC patients (4, 16, 44-47). The main idea in all of these trials was to use
individual patient lung dose volume parameters to guide the tumor dose. The tumor dose
was escalated until the lung dose volume constraints were met. For example, Bradley et al
(16), set lung V20 limits while escalating the tumor dose. They reported that the dose was
safely escalated using 3D-CRT to 83.9 Gy for patients with V20 values <25%, and to 77.4
Gy for patients with V20 values between 25% and 36%. The group reported that elective
nodal failure occurred in less than 10% of all patients. Other studies (46, 47) used the
MLD to determine achievable tumor dose. Belderbos et al (46) escalated the prescription
dose based on MLD. They reported that dose escalation was safe up to 94.5 Gy in 42
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fractions in patients with MLD < 13.6 Gy. They also reported that they found higher
doses were associated with better overall survival for smaller tumor volumes. Baardwijk
et al (48) used a MLD of 19 Gy and a maximum spinal cord dose of 54 Gy to escalate
tumor dose. They reported that their prescribed dose was 64.8 ± 11.4 Gy with a severe
pneumonitis rate (grade 3 or higher) of 21%. A few studies went a step further (4, 44) and
explicitly used NTCP models to determine dose volume constraints that yielded an
acceptable complication probability. Kong et al (4) escalated dose based on the LKB
NTCP model. Using the model, they binned patients into different bins according to the
effective volume Veff. The group defined Veff as the volume of normal lung that would
have to be uniformly irradiated to a given reference dose to result in a similar predicted
level of radiation pneumonitis (4). Overall the group was able to deliver doses ranging
from 63 Gy to 103 Gy in 2.1 Gy fractions. The study reported survival of 4%, 22%, and
28%, for patients receiving 63-69, 74-84, and 92-103 Gy, respectively. Overall, these
results were promising and demonstrate that higher radiation doses can improve overall
survival. Currently, the practice is to prescribe 60 to 70 Gy to the target for NSCLC
patients. All of the dose escalation studies achieved target doses that are higher than those
routinely given in the clinic. The local control and overall survival results were also
promising. Although these studies represent a step in the right direction, it is important to
point out that the models were entirely based on basic dose volume constraints.
Incorporating other, non-dosimetric factors into the model could potentially increase the
accuracy and utility of the model and enable further stratification of patients.
Virtual dose escalation trials
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It is also possible to conduct virtual dose escalation trials where the theoretical
gains in tumor dose can be assessed without the risk of harming patients. Baardfwijk et al
(49) performed a dose escalation trial for 65 NSCLC patients. The group determined an
individual maximal tolerable dose based on dose volume constraints for the lung and
spinal cord. They found that an increase of 5.6% tumor control probability (TCP) could
be gained by using the maximum tolerable dose determined by lung and spinal cord dose
volume constraints. The group progressed the idea of the virtual trial and performed a
prospective feasibility study (50). The study reports that the mean delivered dose was
63.0 ± 9.8 Gy with mild acute lung toxicity rates (1 patient experienced grade 3
pneumonitis). Mackay et al (51) performed a virtual study by prescribing patient dose
based on cellular radiosensitivity. The group simulated varying patient radiosensitivties
based on measured distributions among cancer patients of the surviving fractions of their
fibroblasts given a dose of 2 Gy. They determined that their model showed that
improvements in tumor control rates may be achievable through individualizing
radiotherapy dose prescriptions.
Patient database
One of the largest NSCLC patient databases is collected at MD Anderson Cancer
Center and is described in detail by Jin et al (37). The database includes 576 NSCLC
patients that were treated with definitive radiation therapy at MD Anderson from 19992005. Patients were treated with either 3D-CRT or IMRT. The database contains patients
that were treated with and without chemotherapy. Patients were excluded from the study
if their total dose was <50.4 Gy (which is considered a palliative dose), if they had doses
per fraction that varied over the course of treatment, or had treatment breaks totaling >7
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days.

The database includes clinical, dosimetric, demographic, chemotherapy, and

outcome information. Some specific examples of the recorded information include: dose
volume parameters for the lung, tumor stage and histology, smoking status, pulmonary
function test (PFT) data, nodal status, and fractionation scheme. Radiation pneumonitis
toxicity was scored by a physician on the basis of clinical presentation and radiographic
abnormalities according to the National Cancer Institute’s CTCAE version 3.0 (18). The
clinically significant end point used for the analysis was severe (grades 3-5) radiation
pneumonitis. Grade 3 radiation pneumonitis is defined as severe symptoms, interfering
with activates of daily living, and oxygen indicated. Grade 4 radiation pneumonitis is
defined as life-threatening respiratory compromise and Grade 5 is death due to radiation
pneumonitis. This retrospective study was approved by the Institutional Review Board at
MD Anderson.
In the initial clinical analysis of the data, using univariate analyses, patient
smoking status was the single factor most correlated with radiation pneumonitis. Other
factors correlated with a lower rate of radiation pneumonitis include negative nodal
status, use of 4-dimensional computed tomography (4DCT) simulation, and treatment
with IMRT (37). Jin et al (37) also identified a DVH curve defined by V20 ≤ 25%, V25 ≤
20%, V35 ≤ 15%, and V50 ≤ 10%. In multivariate analysis, smoking status retained
significance independent of dose-volume factors (37). Non-smokers were found to have
the highest risk for radiation pneumonitis while smokers were found to have the lowest
risk for toxicity. Tucker et al (52) found that the volume parameter (n) was not
significantly different from 1, indicating that MLD can be used to predict for radiation
pneumonitis. Tucker et al (52) also presented an NTCP model that included patient
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smoking status and follow up time. The follow up time was included to account for
patients that are censored by incomplete follow-up for any reason (including death) and
takes into consideration patients who would eventually experience toxicity with
sufficiently long follow-up. In other analysis of MD Anderson data, Yuan et al (38) found
that certain genotypic expression of Single Nucleotide Polymorphisms (SNP) were
associated with a lower risk of radiation pneumonitis.
Purpose
Studies have shown that dose escalation can lead to improved tumor control and
subsequently better overall survival for NSCLC patients. However, lung dose is limited
by normal tissue toxicity; mainly radiation pneumonitis. If we were able to more
accurately predict for radiation pneumonitis, we could further personalize radiation
treatment by prescribing a target dose that is tailored to the individual’s risk of
developing radiation toxicity. Currently, prediction models rely on basic indices derived
from the DVH and therefore are too simplistic and not yet accurate enough to be used to
individualize tumor doses. Therefore, the purpose of this study will be to improve the
accuracy of predictive risk models for radiation pneumonitis and to show the dosimetric
benefit of using the models to guide patient treatment planning. The first part of the study
will aim to improve the accuracy of radiation pneumonitis dose response models by
incorporating spatial and functional aspects into the model. The second part of the study
will use a dose response model in a virtual dose prescription trial to determine the
potential dosimetric benefit of using a model to determine target dose.
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Central hypothesis
The fit of radiation pneumonitis dose response models can be significantly
improved by incorporating information about the heterogeneous function of the lung.
Specific Aims
1. To incorporate the spatial location of dose within the lung into the modeling of
radiation pneumonitis.
Working hypothesis: The accuracy of radiation pneumonitis dose response models
can be significantly improved by incorporating information about the spatial
location of dose within the lung.
2. To incorporate ventilation-based functional information into the modeling of
radiation pneumonitis.
Working hypothesis: The accuracy of radiation pneumonitis dose response models
can be significantly improved by incorporating ventilation based functional
information.
3. To determine the potential benefit of using radiation pneumonitis modeling to
optimize target dose for individual patients.
Working hypothesis: The relative median difference in prescription dose between
the model-generated plans and the clinically used plans will be greater than 5 Gy.
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Specific Aim 1: Spatial Study
Introduction
Current models describing the risk of developing radiation pneumonitis are based
on dosimetric indices derived from the DVH. As an example, the MLD and V20 are
metrics that are often used to predict for toxicity (30, 31). By definition, the DVH is a
reduction of the 3D spatial dose distribution into the 2D domain. A single metric, such as
MLD or V20, is an even further simplification of the 2D data. One consequence of the
simplification of the 3D data into a single metric is a loss of spatial information. Spatial
information is important because several researchers have proposed that lung function is
not homogenous and may vary spatially throughout the lung. Specifically, studies have
suggested that patients who get radiation therapy to the base of the lung are more likely to
develop radiation pneumonitis than patients who get radiation to the apex of the lung (30,
32-34, 39, 43, 53). Liao et al (39) irradiated mouse lung and determined that the base of
the lung is more radiosensitive than the apex. In human studies, this data has been echoed
by Yorke et al (32), who calculated various dosimetric indices for different portions of the
lung. They found that that the mean dose to the inferior lung was highly correlated to
radiation pneumonitis. Hope et al (33) and Bradley et al (53) analyzed the spatial location
of GTV centroids and determined that inferior tumor position was indicative of higher
rates of radiation pneumonitis. On the other hand, Robnette et al (36) did not find a
relationship between dose to the lower lung and higher radiation pneumonitis rates.
Overall, the data are inconclusive. Furthermore, the previously reported methods have
limitations. Several authors note that there is a paucity of events in the lower portion of
the lung, making the data unstable in the inferior lobes (33, 54). Many studies have made
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conclusions using the GTV centroid to analyze the spatial effect. However, using the
GTV centroid is not ideal because the GTV centroid acts as a surrogate for the deposited
dose and does not take into account factors such as the volume of the GTV or treatment
planning tendencies and techniques. Another issue arises when researchers analyze GTV
centroid or dose-volume data by dividing the lung into various geometrical regions. The
results of analyzing the date by dividing the lung into regions are sensitive to the location
of the boundaries that define the lung divisions. A more rigorous approach is needed to
study the relationship between the spatial location of the deposited dose and radiation
pneumonitis rates. Therefore, the purpose of this study is to develop a novel method to
incorporate the spatial effect into radiation pneumonitis dose response models and to
apply the method to the MD Anderson clinical NSCLC patient database to determine if
there is a correlation between location and pneumonitis rates. Our hypothesis is that
incorporating spatial information will statistically improve the fit of the predictive model.
The study will be performed in 2 portions. In the first part of the study we will perform
the analysis using GTV centroid information (54) and in the second portion we will
incorporate the entire 3D dose distribution (55).
GTV Centroid analysis
Methods
For this study we used 547 patients from the MD Anderson NSCLC patient
database described in the introduction. The methods of the GTV centroid analysis are
described in detail by Vinogradskiy et al (54). The first step is to de-archive each
patient’s treatment plan into the treatment planning system (Pinnacle3, Philips Medical
Systems, Milpitas, CA). Because, there are several unused treatment plans for each
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patient, the clinically used plan needed to be correctly identified. This was done by cross
referencing treatment planning parameters (prescription, number of beams, beam angles,
monitor units) with the record and verify system and the patient’s paper chart. The rest of
this chapter is taken from Vinogradskiy et al (54).
“ GTV centroid analysis
The treatment plans for all 547 patients were de-archived into the
treatment planning system and the GTV centroid of each patient was mapped onto
one common coordinate system similar to the manner described by Hope et al.
(33). The boundaries of the coordinate system were defined by the extreme points
of each individual patient lung (Figure 2). Once all of the centroids were mapped
onto the

Figure 2: Schematic showing the mapping of GTV centroids from the treatment planning
system (A) to the common coordinate system (B). The rectangles surrounding each lung
indicate the extreme lung points that were used as boundaries to define the common
coordinate system shown in (B). Printed with permission (54).
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common coordinate system, the results were qualitatively analyzed by graphing
the data in a coronal orientation. The data were graphed and displayed according
to disease stage, smoking status, and the presence of severe pneumonitis. To
further analyze the results, we binned the data into equal geometrical regions and
used a chi-square test to determine whether there were statistically significant
differences between the pneumonitis rates in the various lung regions. In order to
further stratify the analysis according to disease stage, pneumonitis rates were
calculated for a smaller cohort of patients with stage I and II disease and for
another cohort of patients with stage III and IV disease.
Modeling methods
We used the LKB model (24) with the volume parameter (n) set equal to
one (52) to calculate NTCP for radiation pneumonitis…The model described in
Eq. 4 represents the conventional dose-volume model incorporating MLD and was
used as the baseline for statistical comparison with a second model that
incorporated GTV centroid location.
To incorporate GTV centroid location into the predictive model we
replaced the quantity t (in Eq. 4) with

,

Equation 7

where C is a model-fitting parameter and L is the GTV centroid coordinate. The
quantity exp(CL) can be thought of as a dose modification factor (DMF) on TD50
and has been proposed (52, 56) as a way to introduce risk-factors into the NTCP
model. Six different orientations were investigated for the GTV centroid
coordinate (L in Eq. 7): superior-inferior (SI), right-left (RL), anterior-posterior
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(AP), medial-lateral (ML), radial, and SI distance from the mean SI position of all
GTV centroids. The radial coordinate was taken as the radial distance from the
center point of the medial edge of each lung box. Anatomically, this coordinate is
analogous to the radial distance from the center point of the mediastinum. Using
maximum likelihood analysis and the likelihood-ratio test, we compared the
model that incorporated GTV centroid information and dose-volume information
(Eq. 7) to the baseline dose-volume model (Eq. 4) to determine whether adding
GTV centroid information significantly improved the fit of the model.
In addition to comparing the GTV centroid location model to the basic
dose-volume model, a comparison was made using our best fitting model to date,
which currently incorporates dose-volume information, smoking status, and
follow-up time (52). Mathematically, smoking status is incorporated into the
model by introducing covariate DMFs that account for smoking status (52). The
follow-up time accounts for patients that are censored by incomplete follow-up for
any reason (including death) and takes into consideration patients who would
eventually experience toxicity with sufficiently long follow-up. The likelihoodratio test was used to compare our current, most accurate model (which
incorporated dose-volume, smoking status, and follow-up time) versus the same
model with the GTV centroid DMF added in. All statistical work was done with
MATLAB software.
Analysis of GTV centroids that exclude nodal volume
Seventy five percent of the patients in our database had stage III or higher
disease, which indicates nodal involvement. The practice in our clinic (and the
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method used for this study) is to contour the primary tumor and nodal volume and
consider that area the GTV. Therefore, the centroids calculated for this analysis
included the primary tumor as well as the nodal volume. The other possibility for
performing this type of analysis is to exclude the nodal volume when calculating
the centroid of the GTV. There are advantages and disadvantages to both
methods. For example, excluding the nodal disease in the centroid calculation has
the advantage of better isolating the spatial location of the primary tumor in the
lung parenchyma. On the other hand, including the nodal volume provides a GTV
centroid that is a better representation of the true location of the deposited dose. In
order to determine whether including nodal volume made a difference in our
results we re-contoured the GTV of every patient to exclude nodal volume, reanalyzed the data, and compared the results to the results obtained while including
the nodal volume in the GTV centroid calculation.
Results
Qualitative GTV centroid results
Of the 547 patients analyzed, 111 (20.3%) experienced severe radiation
pneumonitis. Figure 3 shows a coronal view of all GTV centroids. The mean SI
position of all tumors was located at 0.62 on a scale of 0 to 1 (0 corresponding to
the inferior end and 1 corresponding to the superior end). Graphing of GTV
centroid location according to tumor stage (Figure 4) indicated that the GTV
centroid of patients with Stage III and IV disease appeared to be
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Figure 3: Coronal view of
all GTV centroids (A)
displayed according to the
presence
of
severe
pneumonitis. The coronal
CT slice (B) is shown to
indicate the orientation of
the GTV centroid plot.
Printed with permission
(54).
.

Figure 4: Coronal view of all GTV centroids displayed according to tumor stage.
Printed with permission (54).
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concentrated toward the middle of the grid, which anatomically correlates to the
mediastinum, while the GTV centroids of patients with Stage I and II disease were
scattered toward the periphery of the lung. The average ML GTV centroid
position of patients with stage I and II disease was 0.49 while the average ML
GTV centroid position of patients with stage III and IV disease was 0.34 (where 0
is defined as the medial border and 1 is defined as the lateral border). The
difference in ML GTV centroid position between the two groups is significantly
different (p < 0.001 as calculated by the Wilcoxon rank-sum test). The overall
spatial pattern of the GTV centroid location for patients with and without
pneumonitis appeared to be similar in the cohort of patients with stage I and II
disease (Figure 5) and the cohort of patients with stage III and IV disease (Figure
5). In addition, GTV centroids were stratified by patient smoking status (Figure
6). Qualitatively, the GTV centroids of non smokers are notably absent from the
superior region of the lung. The average SI GTV centroid position of non smokers
is 0.58 (range of 0.23-0.81) while the average SI GTV centroid position for
smokers and former smokers is 0.62 (range of 0.10-1.00). However, the difference
in SI GTV centroid position between the non smokers and former and current
smokers was not significant ( p = 0.172 as calculated by the Wilcoxon rank-sum
test).
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Figure 5: Coronal view of GTV centroids displayed according the presence of severe
pneumonitis for patients who had stage I and II disease (A) and patients who had stage
III and IV disease (B). Printed with permission (54).

Figure 6: Coronal view of all GTV centroids displayed according to smoking status.
Printed with permission (54).
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Figure 7 shows a graphical comparison of the GTV centroids that included
nodal volume (Figure 7A) and GTV centroids where nodal volume was excluded
(Figure 7B). As expected, when nodal volume is excluded, the density of

Figure 7: Coronal view of GTV centroids displayed according to the presence of severe
pneumonitis when nodal volume is included in the GTV centroid calculation (A) and when
nodal volume is excluded in the centroid calculation (B). Printed with permission (54).
the GTV centroids appears to move toward the periphery of the lung away from
the mediastinum. However, the severe pneumonitis events appear to have the
same spatial distribution whether nodal volume is included or excluded.
Pneumonitis Rates
Our study cohort included 325 right-lung tumors and 222 left-lung tumors.
The severe pneumonitis rate was 22.5% (73/325) for the right-lung tumors and
17.1% (38/222) in the left- lung tumors. Table 2 shows the pneumonitis rates
when the lungs are divided into equal thirds in the SI orientation. The pneumonitis
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rate was lowest in the superior portion of the lung (16%); however, the
pneumonitis rates were not significantly different (p=0.376 using the chi-square
test). Table 3 shows the pneumonitis rates when the lung was divided into equal
quartiles.
SI Location
(scale 0-1)
Superior
(0.66-1)
Middle
(0.33-0.66)
Inferior
(0-0.33)

Pneumonitis rate
0.16 (35/218)
0.23 (70/301)
0.21 (6/28)

Table 2. Pneumonitis rates for each superior-inferior third of the lung. Printed
with permission (54).
SI Location
(scale 0-1)
Pneumonitis rate
Superior
(0.75-1)
0.11 (11/100)
Upper Middle
(0.5-0.75)
0.23 (76/327)
Lower Middle
(0.25-05)
0.21 (22/105)
Inferior
(0-0.25)
0.13 (2/15)
Table 3. Pneumonitis rates for each superior-inferior quartile of the lung.
Printed with permission (54).
The pneumonitis rate was lowest in the upper quartile (11%); again, however, the
pneumonitis rates were not significantly different (p=0.056). It should also be
noted that the most inferior quartile displayed a low pneumonitis rate (13%);
however, the number of patients with centroids in this region is small, so the
pneumonitis rate is subject to uncertainty (2 pneumonitis events out of 15 total
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centroids). Because of the paucity of events in the lower quartile the data for the
bottom two quartiles were combined (Table 4). We calculated pneumonitis rates
of 11%, 23%, and 20% for the upper quartile, middle quartile, and lower two
quartiles, respectively.
SI Location
Superior
(0.75-1)
Middle
(0.5-0.75)
Inferior
(0-0.5)

Pneumonitis
rate
0.11 (11/100)
0.23 (76/327)
0.20 (24/120)

Table 4. Pneumonitis rates according to quartiles with the two inferior
quartiles combined. Printed with permission (54).

In order to compare our data with prior literature we stratified our data according
to lobe. Specifically, we set the upper lobe equal to the upper half of the left lung
and upper third of the right lung and the lower and middle lobe aggregate equal to
the lower half of the left lung and the lower two-thirds of the right lung. Dividing
the data in such a manner yielded pneumonitis rates of 18% for the upper lobes
and 24% for the middle and lower lobes. Table 5 shows the pneumonitis rates
when the data is further isolated to a smaller cohort of patients with stage I and II
disease and another cohort of patients with stage III and IV disease. The
pneumonitis rates for stage I and II patients were similar for all 3 regions. The
penumotnies rates were 18%, 17%, and 20% for the superior, middle, and inferior
regions respecitvely. The pneumonitis rate for stage III and IV patients was lower
for the superior portion (15%) than for the middle (25%) or the inferior portions
(22%).
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SI Location
(scale 0-1)
Superior
(0.66-1)
Middle
(0.33-0.66)
Inferior
(0-0.33)

Pneumonitis rate for
stage I + II patients

Pneumonitis rate for
stage III + IV patients

0.18 (7/39)

0.15 (28/181)

0.17 (10/60)

0.25 (62/239)

0.20 (2/10)

0.22 (4/18)

Table 5. Pneumonitis rates divided into thirds for patients grouped according
to disease stage. Printed with permission (54).
Table 6 shows the pneumonitis rates when the lung is divided into SI
thirds for the GTV centroids that excluded the nodal volume. The pneumonitis
rates were 15%, 25%, and 19% for the superior, middle, and inferior portions of
the lung respectively. These numbers are similar to what was reported for the
GTV centroids that included the nodal volume (Table 2).
SI Location
(scale 0-1)
Superior
(0.66-1)
Middle
(0.33-0.66)
Inferior
(0-0.33)

Pneumonitis rate
0.15 (32/218)
0.25 (72/293)
0.19 (7/36)

Table 6. Pneumonitis rates for each superior-inferior third of the lung when
nodal volume is excluded from the GTV centroid calculation. Printed with
permission (54).
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Modeling results
Table 7 shows the modeling parameters, 95% confidence intervals, and
significance results. The comparison of the GTV centroid model and the
conventional dose-volume model did not yield a statistically significant difference
in model fit for the various orientations in GTV centroid spatial location that were
investigated (all p values greater than 0.146). It should also be noted that when
modeling parameters listed in Table 6 were recalculated for the GTV centroids
that excluded the nodal volume, all of the p values remained above 0.05 indicating
that including GTV centroid information does not improve the fit of the model to
the data. Furthermore, Table 7 illustrates that incorporating GTV centroid
information did not increase the predictive power of our current best-fitting model
(all p values greater than 0.259).
TD50 (CI)
Model parameters
MLD
33.8 (29.1 43.1)
MLD + SI Location 32.4 (24.9 49.9)
MLD + AP Location 40.8 (27.4 73.9)
MLD + ML Location 34.2 (26.8 49.7)
MLD + RL Location 30.9(24.5 42.5)
MLD + Radial Location 35.0 (27.2 51.4)
MLD + SI distance
31.4 (27.2 39.9)
from mean SI position

m (CI)

DMF (CI)

0.471 (0.37 0.63)
0.467 (0.37 0.63)
0.469 (0.37 0.63)
0.470 (0.37 0.63)
0.476 (0.37 0.64)
0.469 (0.37 0.63)

1.000
1.096 (0.55 2.01)
0.717 (0.32 1.45)
0.967 (0.49 2.01)
1.246 (0.75 2.50)
0.897 (0.42 2.03)

p
--0.766
0.341
0.920
0.400
0.768

0.482 (0.38 0.66) 2.185 (0.78 13.97)

0.146

Table 7. Statistical comparison of nominal dose-volume model with modified (to include
GTV centroid information) dose volume models according to modeling parameters and
corresponding p values. Abbreviations: GTV = gross tumor volume, MLD = mean lung
dose; CI = 95% confidence intervals, DMF = dose modification factor; SI = superiorinferior, AP = anterior-posterior, ML = medial-lateral, RL = right-left. Printed with
permission (54).
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Model parameters
MLD + Smoking
+ Time Censored
MLD + Smoking
+ Time Censored + SI Location
MLD + Smoking
+ Time Censored + AP Location
MLD + Smoking
+ Time Censored + ML Location
MLD + Smoking
+ Time Censored + RL Location
MLD + Smoking
+ Time Censored + Radial Location
MLD + Smoking +
+ Time Censored + SI distance from SI mean

p
NA
0.802
0.301
0.893
0.259
0.748
0.796

Table 8. Statistical comparison of most accurate current model with most
accurate model modified by GTV centroid location. Abbreviations: MLD =
mean lung dose; SI = superior-inferior, AP = anterior-posterior, ML = mediallateral, RL = right-left. Printed with permission (54).

Discussion
The GTV centroid mapping performed in this study was done in a similar
manner to the methods used by Hope et al. (33) and Bradley et al. (16), who
divided the lung into quartiles and combined the two most inferior quartiles to
account for the paucity of pneumonitis events. Hope et al. (33) reported grade 2
(steroids given for clinically significant pulmonary symptoms) pneumonitis rates
of 9%, 25%, 35% for the upper quartile, middle quartile, and lower two quartiles,
respectively while Bradley et al. (16) reported 4%, 25%, and 35%, for the upper
quartile, middle quartile, and lower two quartiles, respectively. When we divided
our data in a similar manner, we calculated pneumonitis rates of 11%, 23%, and
20% for the upper quartile, middle quartile, and lower two quartiles, respectively.
The pneumonitis rates from the two studies show good agreement in the upper
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two quartiles. However, our results did not show increasing pneumonitis rates
toward the inferior of the lung, as indicated in the study by Hope et al. (33) and
Bradley et al. (16). It is also possible to compare our data with results presented
by Graham et al. (30), who categorized tumor location by lobes and reported
pneumonitis rates of 11% for the upper lobe and 29% for the middle and lower
lobes. Dividing our data according to lobe yielded pneumonitis rates of 18% for
the upper lobes and 24% for the middle and lower lobes. The lower pneumonitis
rate in the upper lobe was reproduced; however, the difference in pneumonitis
rates between the lobes was not as extreme as that presented by Graham et al.
(30). One possible explanation for the discrepancy between the results of our
study and those of the studies by Hope et al. (33), Bradley et al. (16) and Graham
et al. (30) is the limited incidence of GTV centroids near the inferior region of the
lung. Our study and the study by Hope et al. (33) both noted paucity of centroids
and events in the inferior portion of the lung, which implies that pneumonitis rates
can be erratically driven by the presence or absence of a few events.
The modeling results and the data presented in Figure 7 and Table 6
indicate that there is little difference when comparing GTV centroids that include
nodal volume and GTV centroids that exclude nodal volume. Theoretically, there
are advantages and disadvantages to using either method; however, our results
indicate that the inclusion or exclusion of the nodal volume in the GTV centroid
calculation does not influence the relationship between spatial location and
pneumonitis rates.
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Figure 6 illustrates that GTV centroids located in the superior portion of
the lung were associated with smokers and former smokers. The superior portion
of the lung also showed the lowest pneumonitis rates (Tables 2-4).

Several

studies have noted that the risk of developing radiation pneumonitis is influenced
by smoking status (37, 52, 57, 58). Our results indicate that smoking status also
influences the spatial position of the tumor within the lung. This indication may
help explain why lower pneumonitis rates have been observed in the superior
region of the lung (32, 33, 53).
Despite our large patient population, we were not able to significantly
improve the accuracy of the pneumonitis model by incorporating GTV centroid
information. This finding conflicts with other studies, which have reported a
correlation between pneumonitis and radiation to the lower lung. One possible
explanation is the noted (32, 33) paucity of events in the lower lung. Another
potential reason for the discrepancy is that we investigated GTV centroids, while
Yorke et al. (32) and Seppenwoolde et al (43) analyzed dose metrics for various
regions of the lung.
The methods and data presented in this work builds on prior studies and
offers some unique advantages to performing a spatial analysis. This study is done
with a large clinical database of 547 patients, which affords it greater statistical
power. In addition, the method of including GTV centroid location as a DMF in
the predictive model is a rigorous way to analyze the spatial effect because it
explicitly aims to separate the dose volume parameter and the spatial parameter.
Furthermore, the presented modeling method treats GTV centroid location as a
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continuous variable and is therefore not dependant on the location of the lung
division (as is the case when dividing the lung into various regions and calculating
pneumonitis rates). Finally, the data presented in this work studies the relationship
between GTV centroid location and smoking status, disease stage, and whether or
not including nodal volume influences spatial results” (54).
3D Dose Spatial Analysis
Methods
The 3D spatial analysis was performed using the same patient database described in the
introduction. The study was published by Vinogradskiy et al (55) and is quoted here.
“Novel Spatial Analysis
All patient treatment plans were de-archived into the treatment planning
system and the 3D dose distribution of each patient lung was mapped onto one
common coordinate system. The boundaries of the coordinate system were
defined by the extreme points of each individual patient lung (Figure 8). For each
patient, the
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Figure 8: An example of dose from two coronal planes (intended to represent a 3D dose
distribution) mapped from the treatment planning system (A) to the common coordinate
system (B). The common coordinate system for each lung is defined by the extreme
boundaries of that particular lung. The boundaries for the left and right lung are defined
separately. As an example, a rectangle highlights the extreme points of the right lung in the
superior, inferior, medial, and lateral orientations (A). The result is a 3D matrix (B) for
each lung that contains the dose distribution inside that lung and is defined from 0 to 1 in
each orientation. Printed with permission (55).
coordinate system for the right and left lungs were determined separately. For
example, the extreme medial point of the right lung provided the medial boundary
of the right lung coordinate system while the extreme lateral point of the right
lung provided the lateral boundary of the right lung coordinate system. The
boundaries were defined in the same manner for the anterior-posterior (AP) and
superior-inferior (SI) orientations. The end result was a 3D matrix for each lung
that contained the dose distribution inside that lung and was defined from 0 to 1 in
each orientation. The 3D matrix was a masked image of the dose inside the lung,
in other words, each pixel contained a scaled dose value if it was within the lung
and 0 if the pixel was outside of the lung contour. This process ensured that each
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patient’s lung dose distribution was defined from 0 to 1 and was therefore mapped
on the same coordinate system. It should be noted that the lung region of interest
(ROI) was defined as total lung minus GTV.
Once all dose distributions were mapped onto the common coordinate
system the spatial information was incorporated into a predictive radiation
pneumonitis model. To be consistent with the literature, we used the LKB
formulation (24) to calculate NTCP…To incorporate spatial information into the
LKB model, the dose to each voxel was weighted according to its location in the
lung. We started with the mathematical definition of MLD which can be written as

,

Equation 8

where v is the volume, D is the dose, and i loops over all the dose bins. Next, we
modified the term in Equation 8 to define a spatially weighted effective dose that
can be written as

.

Equation 9

Substituting the new effective dose term (Eq 9) and re-writing the parameter t (Eq
4) the new model can be written as
Equation 10
where C is a model fitting parameter and w is a spatial weighting value that comes
from a user-defined spatial weighting matrix. The user-defined spatial weighting
matrix is intended to reflect the spatial pattern that is to be investigated. For this
work, we investigated spatial weighting matrices that contained linearly scaled
values between 0 and 1 according to each of the following orientations: SI, AP,
right-left (RL), medial-lateral (ML), and radial. Conceptually, the higher
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weighting values imply that a particular region is more radiosensitive than the
region described by the lower weighted values. As an example, an SI weighting
matrix (Figure 9A) assumes that the dose to the superior lung voxels is less lethal
than the dose to the inferior lung voxels while a radial weighting matrix (Figure
9B) assumes the dose to the periphery of the lung is more lethal than the dose
closer to the mediastinum.

Figure 9: An example slice of a superior-inferior weighting scheme (A), a radial weighting
scheme (B), and a ramp function weighting scheme (C). The CT images are included to
indicate the orientation of the weighting slices. Printed with permission (55).

In addition to linear SI weighting, we investigated a ramp function weighting
scheme. The ramp function weighting scheme originated from our previous GTV
centroid analysis which found pneumonitis rates of 11%, 23%, and 20% for the
superior, middle, and inferior portion of the lung respectively (54). The ramp
function weighting scheme (Figure 9C) weighs the superior voxels by 0 and
linearly increases the weighting towards 1 for the middle and inferior portions of
the lung. The model fitting parameter C allows the relative contribution of the
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spatially weighted voxels to change based on the entire population. The sign of
the parameter C provides information on whether the optimal fit of the model is
along the direction of the weighting scheme chosen (positive C value) or against
the direction of the weighting scheme chosen (negative C value). The TD50, m,
and C parameters were all fit to our dataset. To test the significance of
incorporating spatial information into the LKB model the likelihood ratio test was
used. Specifically, the fit of the model that incorporated spatial and dose-volume
information (Eq. 10) was compared to the fit of the dose volume model (Eq. 4) to
determine whether adding spatial information significantly improved the fit of the
model to the data. We present the significance value (p) that demonstrates whether
or not there was a statistically significant improvement in the model fit.
Lung Division Analysis
As a byproduct of the lung-mapping method described in the previous
section it is trivial to write computer code to divide the lung into various
geometrical regions and study the correlation between local dosimetric parameters
of each lung region and radiation pneumonitis rates. In order to compare our
results with previous work, we divided the lungs according to volume into equal
geometrical halves (superior and inferior half) and equal geometrical thirds
(superior, middle, and inferior third). A mean dose was calculated for each local
region. A multivariate logistic regression analysis with stepwise inclusion of
factors was used to determine which local mean dose was independently
correlated with radiation pneumonitis. Furthermore, we tested whether the mean
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dose to any one particular region was a better predictor of radiation pneumonitis
than the overall MLD.
Results
Of the 547 patients analyzed, 111 (20.3%) experienced severe (grade 3 or
greater) radiation pneumonitis. Table 9 shows the model fitting parameters, 95%
and 68% confidence intervals, and the p values for the various weighting schemes
investigated.

Model
parameters

Orientation of
matrix
NA

MLD
MLD + SI
Weighting
MLD + AP
Weighting
MLD + ML
Weighting
MLD + RL
Weighting
MLD + Radial
Weighting
MLD + ramp
function
Weighting

0 = superior
1 = inferior
0 = anterior
1 = posterior
0 = medial
1 = lateral
0 = right
1 = left
0 = central
1 = distal
0 = superior
1 = inferior

TD50
(CI95)
(CI68)
34.6
(30.1 45.3)
(31.9 38.7
29.8
(19.2 99.2)
(23.1 44.3)
27.0
(14.00 732)
(18.4 51.3)
37.3
(16.64 inf)
(22.7 117.8)
32.9
(25.1 51.8)
(28.3 39.9)
14.1
(10.3 inf)
(14.4 56.1)
21.1
(11.3 inf)
(14.5 41.6)

m
(CI95)
(CI68)
0.488
(0.38 0.67)
(0.42 0.57)
0.478
(0.37 0.66)
(0.41 0.56)
0.488
(0.38 0.67)
(0.43 0.57)
0.489
(0.38 0.67)
(0.42 0.57)
0.491
(0.38 0.67)
(0.42 0.57)
0.495
(0.37 0.68)
(0.42 0.58)
0.470
(0.36 0.65)
(0.41 0.55)

C
(CI95)
(CI68)

p

NA

NA

-0.292
(-0.99 3.46) 0.6468
(-0.72 0.54)
-0.484
(-1.36 41.5) 0.6330
(-1.05 1.01)
0.160
(-1.1103 inf) 0.9034
(-0.7 4.8)
-0.123
(-0.70 0.81) 0.7189
(-0.43 0.26)
-0.394
(-1.44 inf) 0.5742
(-1.18 1.20)
-0.418
(-0.74 inf) 0.4176
(-0.63 0.20)

Table 9. A comparison of model parameters and significance values for the various
weighting schemes investigated. Abbreviations: CI95 = 95% confidence intervals, CI68 =
68% confidence intervals, MLD = mean lung dose; SI = superior-inferior, AP = anteriorposterior, ML = medial-lateral, inf = infinity, RL = right-left. Printed with permission (55).
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The comparison of the conventional dose volume model and the spatially
weighted dose model did not yield a statistically significant difference in model fit
for any of the spatial weighting schemes. These results suggest that taking
individual voxel location into account does not significantly improve the fit of the
model.
When dividing the lung into two halves, both the mean dose to the
superior half and the mean dose to the inferior half were associated with severe
pneumonitis. In a stepwise logistic regression analysis, using the mean dose to the
superior half, the mean dose to the inferior half, and the overall MLD, the overall
MLD was selected at the 0.05 significance level. When dividing the lung in thirds,
the mean dose to the middle third was the only dosimetric quantity associated
with severe pneumonitis. It is also important to note that the log-likelihood using
the overall MLD was greater than the log-likelihood using the middle region mean
dose, indicating that the overall MLD was more accurate in predicting radiation
pneumonitis than was the mean dose to the middle third. The scatter plot in Figure
10 indicates that when the mean doses to the three regions (inferior, middle, and
superior) were compared against the overall MLD, the mean dose to the middle
lung region is most correlated with the overall MLD.
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Figure 10: Scatter plots showing a comparison between the total mean lung dose and the
superior region mean dose (A), middle region mean dose (B), and inferior region mean
dose (C). The severe pneumonitis events are shown as red circles while the non
pneumonitis events are displayed as black stars. Printed with permission (55).
Discussion
The presented work proposes a novel method to study the relationship
between the spatial location of the deposited 3D lung dose distribution and
pneumonitis rates. The method proposed in this study builds on prior work and
provides unique advantages to performing a spatial dose analysis. In previous
work, there have been two general approaches to studying the relationship
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between the spatial effect and pneumonitis rates. These approaches involve
dividing the lung into various geometrical regions and studying the dosimetric
indices derived from them (34, 43) or studying the GTV centroid locations (30,
33, 53). As noted by Hope et al. (33), the GTV centroid acts as a surrogate for the
location of the deposited dose and does not take into account GTV volume or
treatment planning techniques. In addition, the results of both methods are
sensitive to the location of the boundaries that define the lung divisions. The
spatial weighting method proposed in this work incorporates the entire 3D dose
distribution and treats each orientation as a continuous variable and therefore the
results do not depend on how the lung is divided. Furthermore, after all the dose
distributions have been mapped onto the common coordinate system, it is then
possible to divide the data along any geometrical boundaries without the laborious
process of re-contouring and re-calculating dosimetric parameters in the treatment
planning system. In this work, we divided the lung into two and three equalvolume superior-inferior regions. However, it would be a matter of a few lines of
computer code to divide the dose distributions into any number of divisions along
any orientations. Finally, incorporating the spatial dose information into the LKB
model and testing for a statistically significant increase in model accuracy allows
for a way to mathematically separate spatial location and dose volume effects. We
believe this is a more rigorous approach to determining whether the spatial
location of the deposited lung dose is correlated with pneumonitis rates.
When dividing our data in a similar manner to Yorke et al. (34) (into a
superior and inferior region) we found that both regions were significantly
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associated with radiation pneumonitis at the 0.05 significance level. While Yorke
et al. (34) found that only dosimetric indices to the inferior lung region were
associated with radiation pneumonitis. Both studies confirmed that dosimetric
indices to the entire lung were correlated with pneumonitis. One possible
explanation for the disagreement in the results to the superior lung region is the
overall location of the deposited dose in the two study populations. When dividing
the lung into three regions we found that only the middle region mean dose was
associated with radiation pneumonitis and the scatter plot (Figure 10) confirmed
that the overall MLD values are most closely resembled in the middle portion of
the lung. Most of the patients in our database have clinical stage III or higher
disease and the dose to the middle portion of the lung is a product of irradiating
the nodes in the mediastinum. Therefore, the best representation of the overall
MLD is the mean dose to the middle portion of the lung. It is also important to
note that when dividing the lung into regions we found that the best predictor of
pneumonitis was the overall MLD and not the mean dose to any one particular
region confirming that for our data there is no additional benefit to analyzing
different portions of the lung.
The modeling and lung division results indicate that for our patient cohort
the spatial location of the deposited lung dose does not influence the risk of
radiation pneumonitis. This finding is generally not in agreement with the other
studies which indicate a relationship between dose to the inferior lung and
pneumonitis rates (30, 33, 34, 53). For example, Hope et al. (33) report grade 2
(steroids given) pneumonitis rates of 9% for the upper quartile of the lung, 25%
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for the middle quartile, and 35% for the lower two quartiles and Bradley et al.
(53) cite 4% for the upper quartile, 25% for the middle quartile, and 35% for the
lower two quartiles. When we divide our data in a similar manner, we calculated
pneumonitis rates of 11%, 23%, and 20% for the upper, middle, and lower two
quartiles respectively (54). Comparing our data with the studies performed by
Hope et al. (33) and Bradley et al., (53) there is good agreement in the upper two
quartiles; however, our study does not show decreasing pneumonitis rates towards
the inferior of the lung. There are several possible explanations for the differing
results. One possible explanation is the difference in methods used to perform the
analysis. The studies mentioned above analyzed GTV centroid location while the
current study uses the 3D dose distribution. Another possible explanation for the
discrepancy is the differing patient populations. As noted earlier, our study
contains patients mostly with stage III and higher disease. As a result of
irradiating the nodes in the mediastinum most of the dose is concentrated in the
middle portion of the lung. Therefore, it is possible that most of the valuable
dosimetric information is contained within the middle portion of the lung, overriding any superior-inferior spatial effect. Another possible explanation for the
differing results is the lack of information towards the inferior portion of the lung.
The Hope et al. (33) study and our study (54) both note a lack of centroids
towards the inferior lung. The lack of centroids in the inferior lung implies that
pneumonitis rates can be erratically driven the presence or absence of a few
pneumonitis events.

46
The novel method was applied to a patient database and it was determined
that for our patient cohort the spatial location does not influence the risk of
pneumonitis. Because of the number of patients in our study and the rigor of our
novel spatial method we believe that the current work adds an important clinical
contribution to existing knowledge about the spatial effect in the lung” (55).
There were several limitations to our spatial analysis. We used the LKB MLD model to
perform the modeling in this study. We chose this model because it is consistent with
what has been cited in the literature (6) and consistent with the methods we previously
used to analyze our data (37, 52). In future work, it would be interesting to incorporate
spatial information into other mathematical forms of dose response models (26, 27) and
test for whether the fit of the model is improved. In addition, as more patient data is
collected, it would be informative to perform a 3D spatial analysis for patients grouped by
their clinical stage to further isolate the spatial effect.
Conclusions
A novel method using the GTV centroid and the 3D spatial dose distribution was
proposed to investigate the relationship between the location of the deposited lung dose
and pneumonitis rates. The method provides unique advantages in that it: incorporates the
entire 3D dose distribution, treats spatial information as a continuous variable, and aims
to mathematically separate spatial and dose volume effects. The novel spatial method was
applied to a large 547 NSCLC patient database. The hypothesis of this study is rejected;
incorporating spatial information did not improve the fit of the model to the data.
Although our results showed lower pneumonitis rates for the superior portion of the lung,
we did not find an overall trend of increasing pneumonitis rates toward the inferior
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portion of the lung. Furthermore, for our patient cohort, incorporating GTV centroid
information or 3D spatial information did not lead to a statistically significant gain in
pneumonitis model fit, indicating that for our patient cohort the spatial location of the
deposited dose not influence the risk of pneumonitis (54, 55).
Specific Aim 2: Ventilation study
Introduction
For lung cancer patients, lung function may not be homogeneous and may vary
throughout the lung. Lung function can be heterogeneous because of the tumor, prior
existing lung conditions such as emphysema and chronic obstructive pulmonary disease
(COPD), or the inherent heterogeneity of the lung parenchyma. Currently, NTCP models
rely on basic dose-volume metrics (such as MLD and V20) and do not take into
consideration the heterogeneous lung function. Several researchers have proposed to
incorporate imaging to assess lung function and to predict for thoracic toxicity (40-43,
59-62). Most of the studies have investigated either SPECT based perfusion imaging or
CT imaging. Nioutsikou et al (42) and Miften et al (41) provide methodology on
incorporating SPECT-based functional imaging into predictive modeling. Seppenwoolde
et al (43) studied the regional lung differences using perfusion. Ma et al (63) reported a
weak correlation between CT-based density changes and PFT results. However, besides
CT and SPECT-based perfusion, few imaging modalities have been incorporated into the
evaluation of normal tissue toxicity. One potential way to assess lung function is through
ventilation. As noted by Vinogradskiy et al (64)…
“An exciting and new form of ventilation imaging has been proposed by Guerrero
et al. (65). These authors proposed to use 4-dimensional computed tomography
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(4DCT) data to calculate ventilation. A 4DCT data set consists of 3-dimensional
(3D) CT images resolved into different phases of the breathing cycle (66, 67).
Because 4DCT data are routinely acquired for thoracic radiation therapy treatment
planning, calculating ventilation maps from 4DCT data does not add any extra
dosimetric or monetary cost to the patient. Several groups have investigated
different aspects of ventilation imaging (44, 65, 68-71). For example, Yaremko et
al. (59)\ discussed the idea of designing treatment plans to avoid highly ventilated
areas of the lung, Ding et al. (72) studied the changes in lung ventilation after
radiation therapy, Castillo et al. (73) explored the different ways of calculating
ventilation from 4DCT data with corresponding comparative evaluation with
clinically acquired SPECT ventilation, and Yamamoto et al. (69) investigated
4DCT based ventilation imaging for patients with emphysema” (64).
The detailed methodology of calculating ventilation maps from 4DCT data is described in
detail by Vinogradskiy et al (64).
“The first step is to export all of the phases of the 4DCT dataset and
appropriately segment both lungs on the exhale and exhale CT datasets. Lung
segmentation was performed by delineating lung voxels with CT values from -999
to -250 and by using a three-dimensional morphological growing algorithm (73) to
delineate the trachea, main-stem bronchi, and pulmonary vasculature” (64).
An example axial and coronal slice of segmented lung is shown in Figure 11.
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Figure 11: An example of segmented lung. The sagittal and axial planes are shown. It
should be noted that the vasculature within the lung is excluded.
The remaining steps of calculating ventilation images are described by Vinogradskiy et al
(64).
“Once the lungs were segmented, deformable image registration using trajectory
modeling (74) was used to link corresponding lung volume elements together
between the inhale and the exhale data sets (Figure 12). It should be noted that 5
phases (half of the breathing cycle) were used for the registration algorithm and
the segmentation used for the registration algorithm was more coarse than the
procedure used for the ventilation image segmentation. The spatial accuracy of the
registration algorithm has been
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Figure 12: An example of a vector map showing the deformation field. The deformation
field links lung voxels together from the inhale phase to the exhale phase of the 4DCT
dataset.

reported to be 1.25mm (74). Following spatial registration, corresponding
Hounsfield units were input into a density-change-based model. The model can be
mathematically written as
, Equation 11
where Vin and Vex are the inhale and exhale volumes and HUin and HUex are the
inhale and exhale Hounsfield units of the individual lung voxels. The theory
behind Equation 11 stems from the assumption that CT voxel content is composed
of a linear combination of water-like material with a CT value of 0 and air-like
material with a CT value of -1000 (75). Explicit derivation of Equation 11 is
provided by Castillo et al. (73). The left side of the equation represents the local
physiologic specific ventilation and the resulting 3D image displays the
ventilation throughout the lung (Figure 13)…
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Figure 13: An example of a ventilation image overlaid on a coronal CT slice.
There were several steps taken to address the uncertainties in the
ventilation image calculation process. We used 9x9x9 mm voxel averaging to
account for noise in the CT image as well as any spatial errors in the deformable
image registration algorithm. We visually inspected each ventilation image to
check for image artifacts. Whenever relevant, we would re-segment the lungs in
an attempt to mitigate the image artifacts. Furthermore, we manually checked
each deformation map for any errors and discontinuities and if it would have been
necessary we were prepared to rerun the deformation algorithm with different
inputs in an attempt to gain a more spatially accurate deformation map. In
additional, the ventilation images were assessed for self consistency (73). To
assess for self consistency we compared the measured differences in lung volume
with the ventilation-calculated differences in lung volume. The measured
differences in lung volume were determined by taking the difference between lung
volume of corresponding inhale and exhale image pairs. The calculated lung
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volume difference was determined by summing the voxel ventilation for the
segmented lung.”
It should be noted that other groups have proposed a different method of producing
ventilation maps from 4DCT data. These methods calculate the Jacobian of the
deformation field (68, 72) to produce ventilation maps. Castillo et al (73) have noted the
similarities and differences between the density based method and the Jacobian based
method of calculating ventilation images. Their main findings is that the Jacobian based
method calculates a change in voxel volume while the density change based method
calculates the change in air concentration in a particular voxel.
There is potential for this new and exciting way of calculating ventilation to be
incorporated into radiation pneumonitis dose response modeling. Therefore the purpose
of this study was to incorporate ventilation based functional information into the
modeling of radiation pneumonitis. Our hypothesis was that the accuracy of radiation
pneumonitis dose response models can be significantly improved by incorporating
ventilation based functional information.
The study will be divided into 2 portions. The first portion will use weekly
calculated ventilation images to investigate the mid-treatment changes in lung function
that occur throughout the course of radiation therapy. It should be noted that this is
strictly not a modeling study but rather an exploratory investigation to assess ventilation
change throughout the course of radiation therapy. Specifically, we wanted to quantify
the ventilation change as a function of dose and as a function of anatomy. The second part
of the study will aim to explicitly incorporate pre-treatment ventilation imaging into the
modeling of radiation pneumonitis.
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Serial Ventilation Study
Methods
The serial ventilation study is presented from the manuscript published by Vinogradskiy
et al (64).
“ Patient selection
All the patients for this study were chosen from a previous protocol that
was approved by our Institution’s Review Board. Under the protocol, patients
underwent weekly 4DCT scans for the duration of their therapy (76). The protocol
was designed to assess weekly lung volume change and weekly lung tumor
motion. To be eligible for the study, patients had to have a pathological diagnosis
of NSCLC, and their course of radiation therapy had to be scheduled for at least 4
consecutive weeks. During the 4DCT scans, patients were immobilized using a
VacLoc immobilization device (Med-Tech, Orange City, IA). The 4DCT images
were acquired using cine mode on a multisclice helical CT scanner (Discovery
PET/CT; GE Healthcare, Waukesha, WI). A physicist was present during each
4DCT scan to make sure the patient’s breathing was not erratic; however, no
attempt was made to make breathing equivalent from week to week. We chose 6
patients for our study from this protocol. The patients were chosen retrospectively
to represent a wide range of clinical scenarios.
The treatment characteristics of all 6 patients are listed in Table 10 and the
patient and tumor characteristics are listed in Table 11. Two of the patients were
treated with proton therapy, and 4 patients were treated with IMRT. Two patients
experienced severe (grade 3-5) radiation pneumonitis, and 3 patients had prior
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lung diseases (such as emphysema and COPD). Each patient had either 7 or 8
4DCT datasets, the first of which was acquired prior to the beginning of
treatment.”

Patient

Treatment
Modality

1
2
3
4
5
6

Proton
IMRT
Proton
Proton
Proton
IMRT

Presence of severe
Mean Lung
Prescription
pneumonitis (time
Dose (Gy)
to toxicity)
35 x 2.5 Gy
12.14
Yes (148 days)
35 x 2 Gy
16.81
no
37 x 2 Gy
14.05
no
37 x 2 Gy
19.27
no
37 x 2 Gy
19.63
Yes (246 days)
33 x 2 Gy
19.02
no

Table 10. Summary of treatment characteristics.

Patient Age

Gender

Prior Lung
Tumor
Tumor location
Disease
Stage

Tumor Histology

COPD,
Left lower lobe
Emphysema

Non-differentiated
NSCLC
Non-differentiated
NSCLC
Squamous cell
Squamous cell
Squamous cell
Squamous cell

1

73

M

IB

2

67

M

none

Right upper lobe

IIIB

3
4
5
6

68
71
77
72

M
F
F
M

none
none
COPD
Emphysema

Left upper lobe
Left lower lobe
Left upper lobe
Right lower lobe

IIIB
IIIA
IIIB
IIIA

Table 11. Summary of patient and tumor characteristics.

The ventilation images were calculated (using the methods previously described) for each
week for every patient. The ventilation image processing was done in the manner
described by Vinogradskiy et al (64).
“Ventilation image processing
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Once all the ventilation images were calculated, the next step was to
normalize the data. We normalized the data by converting ventilation images to
percentile images (59, 65, 73). Converting ventilation maps to percentile images
as a normalization method was advantageous because it was the method least
sensitive to the maximum ventilation value on a particular image. In other words,
an erroneous hot spot minimally affected the scaling of the rest of the image. The
percentile was determined by ordering the ventilation values and for each value
calculating the percent that fell below that certain value.
To perform a quantitative analysis, it was necessary to have all the weekly
ventilation images defined on the same coordinate system. Because the ventilation
image is defined on the exhale CT coordinate system, we could register the exhale
CT data sets and then apply the same transformations to the ventilation images.
For each patient, we registered the exhale CT data set of each week to week 0
(which we define as the pre-treatment CT data set) using deformable image
registration (77). All registrations were visually inspected by overlaying each
week’s exhale CT data set with the week 0 data set for that particular patient.
Once the CT data were registered, the deformable transformations were applied to
the ventilation maps.
Having all the ventilation images defined on the same coordinate space
enabled us to perform a quantitative analysis. We performed a quantitative
analysis by defining ROIs and tracking the ventilation values of those ROIs
throughout each week of therapy. We defined ROIs in two ways: according to
dose and according to anatomy. For the dose ROIs, we defined the ROI as the
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volume that received greater than or equal to 20 Gy (V20). The V20 was chosen
because it is a common metric used in thoracic treatment planning and evaluation.
We defined the anatomical ROIs by contouring the lobes of both the left and right
lungs. Once the dose and lobe ROIs were defined we calculated the average
percent ventilation for each ROI. The lung mask described was applied to the
ventilation images at every time point. Therefore, the tumor volume was masked
out for each weekly ventilation image. It should be noted that one patient had a
tumor volume that occupied the entire lung lobe during pre-treatment. Therefore,
for that particular patient we excluded the week 0 data point. In summary, our
data included percent ventilation values for each patient, each week, and each
lung lobe as well as percent ventilation values for each patient, each week and
each V20 region.
To study ventilation change throughout treatment, we made a plot of the
average percent ventilation for each ROI as a function of treatment week and
performed a linear fit to the data (Figure 14). The slope of the linear fit was the
metric used to evaluate ventilation change throughout treatment. A positive slope
indicated an increase in ventilation in a particular ROI throughout treatment; a
slope of 0 indicated no change in ventilation; and a negative slope indicated a
decrease in
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Figure 14: An example of ventilation data and the linear fit for 2 different lobes. The slope
of the fit to the lobe 2 data was 3.43, while the slope of the fit to the lobe 1 data was 0.2,
which indicated that lobe 2 showed an increase in ventilation over the course of treatment
and lobe 1 had little to no change in ventilation over the course of treatment.
ventilation. As an example, Fig. XX shows a lobe that had an increase in
ventilation throughout treatment and a lobe that had little to no change in
ventilation.
Analysis of ROI data
The V20 ROI ventilation and slope data were used to study how ventilation
changed throughout treatment as a function of dose. Specifically, we calculated
the change in percent ventilation for the V20 ROI from pretreatment (week 0) to
the final week of treatment. To evaluate the general trend in ventilation change
with dose, we used the slope of the linear fit to the V20 ROI data.
In addition to dose, the ventilation in the different lobes of the lung was
evaluated. Anatomically, ventilation is affected by airway opening or constriction,
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and the best way to investigate this physiologic phenomenon using the available
data is to organize the data according to lung lobe. First, we evaluated only the
pretreatment (week 0) ventilation data. We grouped all the lobes into 2 categories,
lobes that contained the GTV and lobes that did not contain GTV, and evaluated
the average ventilation for each group. We categorized the lung lobes in this
manner because we hypothesized that lobes that contained GTV were more likely
to experience airway constriction and ventilation would therefore be significantly
lower for those lobes.
Next, the lobe data were evaluated for all the treatment weeks.
Particularly, we studied the slope of the linear fit to the lobe ROI data. We
grouped all the lobes into 2 categories: lobes that contained GTV volumes that
shrank and lobes that either did not contain the GTV or where the GTV did not
get smaller. The slopes of the linear fit were statistically compared between the 2
groups of lung lobes using a t-test. Our hypothesis was that throughout treatment,
the tumor was likely to decrease in volume and cause airway opening for a
particular lobe and therefore one would expect the ventilation to increase
throughout treatment for that particular lobe.
Results
Ventilation as a function of dose
The ventilation data for the V20 ROIs are displayed in Table 12.
Ventilation increased in 4 patients and decreased in 2 patients between the final
week of radiation therapy and week 0 (defined as pre-treatment). Four patients
had a positive slope (slopes of 1.1, 1.4, 1.5, 0.3) of the linear fit to the ventilation
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versus week data, indicating an increase in ventilation for the V20 region over the
course of treatment. Two patients had a negative slope (-0.6, -0.5), indicating
decreased ventilation. We found no consistent relationship between dose and
ventilation; ventilation increased in some patients over the course of treatment and
slightly decreased or did not change in others.
Final Week of
Difference in Percent
Week 0 Percent
Slope of linear fit
therapy Percent
ventilation between
Patient Ventilation for
to Ventilation data
Ventilation for V20 the final week and
V20 ROI (%)
(%/Week)
ROI (%)
week 0 (%)
1
56.5
54.1
-2.5
0.3
2
30.1
35.8
5.7
1.1
3
46.9
51.4
4.5
1.4
4
34.7
43.4
8.6
1.5
5
56.8
58.6
1.8
-0.6
6
54.1
53.2
-0.9
-0.5
Table 12. Percent ventilation data for ROIs defined according to V20.
Pretreatment ventilation by lobe
Visually, pretreatment ventilation appeared to be lower in lobes that
contained tumor. The decrease in ventilation was particularly evident when the
tumor was occluding a central bronchial airway; a representative case is shown in
Figure 15. To quantify this phenomenon, the lobes were categorized into 2
groups: lobes that contained tumor and lobes that did not contain tumor. The
average pretreatment percent ventilation was 39±14% (mean ± standard deviation)
for lobes that contained tumor and 54±15% for the lobes that did not contain
tumor (Figure 16). The difference in ventilation between the 2 groups was
statistically significant (p=0.017 using a t-test).
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Figure 15: The dose distribution (A) and percent ventilation maps (B) for patient 2. The
data for this patient provides a representative example of decreased ventilation for the left
upper lobe where the tumor caused a central bronchial occlusion.

Figure 16: Comparison of ventilation between lobes that contained tumors and lobes that
did not contain tumors. The difference in average percent ventilation was shown to be
statistically significant (p=0.017 using a t-test).
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Change in ventilation by lobe over the course of treatment
Two distinct patterns emerged when we qualitatively analyzed the series
of weekly ventilation images for each patient. When tumor volume was visibly
reduced, ventilation appeared to increase in the lobe where the tumor volume was
reduced. A representative case is shown in Figure 17. When tumor volume was
not visibly reduced, the 3D ventilation distribution did not change throughout
treatment. A representative case is shown in Figure 18. To assess both trends
quantitatively, we grouped the lobes into 2 categories: lobes that contained GTV
volumes that shrank and lobes that either did not contain the GTV or where the
GTV did not get smaller. The GTV volume reduction for each patient is shown in
Table 13. Except for patient 3, all patients experienced a decrease in GTV volume
from pre-treatment to the final week of treatment. Therefore, we grouped lobes
that contained tumor for patients 1,2,4,5,6 into one group and lobes that did not
contain GTV for patients
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Figure 17: Tumor outline and dose distribution (A) as well as the weekly progression of
ventilation images (B) for patient 4. This patient provides a representative example of
increasing ventilation in the left upper lobe as the tumor decreases in size.

Figure 18: Tumor outline and dose distribution (A) as well as the weekly progression of
ventilation images (B) for patient 3. This patient provides a representative example of a
case where there was no visual evidence of the tumor volume reduction and as a result the
ventilation distribution remained unchanged throughout treatment.
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Patient
1
2
3
4
5
6

Week 0 Volume
(cc)
339.6
37.5
45.3
178.8
266.1
100.6

Final Week Volume
(cc)
148.7
21.5
45.3
93.8
63.3
72.1

Percent difference
(%)
-56.2
-42.5
0.1
-47.6
-76.2
-28.3

Table 13. GTV volume for each patient recorded during pre-treatment and during the
final week of therapy.

1,2,4,5,6 and all lobes for patient 3 into another group. The slope of the linear fit
to the weekly ventilation data was assessed for both groups. The average slope
was 1.18±1.49 for the group that contained tumors that shrank and -0.32± 1.37 for
the group that did not contain tumor (or contained tumors that did not get
smaller). The results were statistically different between the 2 groups (p=0.014
using a t-test). A slope of 1.18 indicates that ventilation increased throughout
treatment, while a slope of -0.32 is taken to mean little to no change in ventilation
throughout treatment. The quantitative results confirm the visual observation that
ventilation increased as the tumor shrank and remained unchanged when there
was no change in the tumor and the surrounding thoracic anatomy.
Discussion
The ventilation results obtained using the dose (V20) ROIs suggest that
there is no clear relationship between dose and ventilation function. For some
patients, ventilation increased as a function of dose, and for others, ventilation
remained unchanged or slightly decreased as a function of dose. These results are
in line with the mixed data reported by Ding et al. (72), who found decreasing
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ventilation for lung regions receiving greater than 24 Gy, and decreasing and
increasing ventilation for lung regions receiving less than 24 Gy. It should be
noted that our methods of calculating ventilation were slightly different than those
used by Ding et al. (68, 72). Furthermore, another difference between the studies
is that the post radiation therapy 4DCT images from the Ding et al. (72) study
were not acquired during the last week of radiation therapy, as was done for our
study. The biggest factor impacting ventilation is airway obstruction, and in the
case of lung cancer, airway obstruction is most influenced by anatomical changes
to the tumor. In our study, we believe that the lack of a clear relationship between
dose and ventilation was related to the lack of a consistent relationship between
dose and changes to the tumor. In some cases, radiation dose caused the tumor to
shrink significantly, which led to airway opening and an increase in ventilation;
while in other cases, radiation dose had little impact on the tumor size and the
surrounding anatomy, causing either a slight decrease or no change in ventilation.
Whether or not radiation alone (with no accompanying changes to the tumor)
causes a decrease in ventilation is a topic of ongoing research. The dose and lobe
results for the 6 patients in our study indicate that when there is no change in the
thoracic anatomy, radiation damage to the lung alone does not cause a
measureable decrease in ventilation. However, it is possible that the re-ventilation
due to airway opening masks the effect of ventilation decrease due to radiation
induced lung damage. Furthermore, it is possible that the uncertainties involved
in the ventilation image calculation process also mask the dose effects.
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When looking at the pretreatment ventilation data, both the representative
case (Figure 15) and quantitative (Figure 16) results suggest that lobes that
contained tumors had a lower ventilation value and were therefore less functional.
This result can be explained physiologically by the fact that the tumor caused a
bronchial airway occlusion and the lobe was consequently less ventilated (Figure
15). The airway occlusion appears clearly on the ventilation map but is not as
obvious on a conventional CT scan. Since 4DCT scans are acquired as part of
routine clinical care, the extra lung function information comes at no extra
dosimetric or monetary cost to the patient. A ventilation image that shows obvious
ventilation defects (Figure 15) could potentially be used to optimize treatment
plan design, as described by Yaremko et al. (59). However, further work is needed
to verify the ability of 4DCT-based ventilation imaging to identify ventilation
defects due to airway occlusion caused by tumors. In the current work, data for 6
patients was analyzed; an ideal study would include more patients and compare
defects measured using 4DCT-based ventilation against defects measured using
SPECT-based ventilation imaging. Preliminary work by Castillo et al. (59, 73)
suggests that the highest correlation between 4DCT-based ventilation and
SPECT-based ventilation occurs for the lowest percent ventilation values
(ventilation defects).
The qualitative (Figure 17 and Figure 18) and quantitative weekly results
suggest that 2 distinct phenomena occurred. When tumor volume was reduced and
an airway was opened, spatial ventilation was likely to increase; when there was
no change in tumor or thoracic anatomy, ventilation was likely to remain the same
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or decrease slightly. Ding et al. (72) performed a similar analysis looking at the
ventilation change for ipsilateral and contralateral lung. They reported a larger
increase in ventilation in the ispsilateral lung than the contralateral lung.
Seppenwoolde et al. (43) also noted re-ventilation (and reperfusion) as a function
of the changing tumor anatomy. Our results and those reported by Ding et al. (72)
and Seppenwoolde et al. (43) can be explained by the physiology of ventilation. A
ventilation defect is likely to occur if an airway is blocked, and ventilation is
likely to improve if the tumor decreases in size and an airway is opened.
We chose to normalize the ventilation images by converting them to
percentile maps based on methodology previously used in the literature (59, 65,
73) There are other normalization methods that can be used. For example, the
ventilation image could be normalized by dividing by the maximum pixel value in
a particular image or by normalizing images for all weeks by a pre-determined
ventilation maximum. Seppenwoolde et al. (43) normalized SPECT based
perfusion images used for a longitudinal study on low dose (< 8Gy) and highly
perfused regions of the lung. In the case of weekly 4DCT-based ventilation
images we believe converting to a percentile image is ideal because it is the
method least sensitive to the maximum ventilation value on any particular image
and because each week’s ventilation image is normalized to itself. Normalizing
each week’s ventilation image to itself is advantageous because patients may be
breathing with different amplitudes during each treatment week.
There were several limitations to our study. Although much progress has
been reported on 4DCT-based ventilation imaging (59, 65, 68-71), the methods
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for calculating ventilation are still being perfected. For example, 4DCT-based
ventilation calculations are sensitive to image registration spatial errors, and
several groups are working on methods to mitigate the effect of the registration
uncertainties (72, 74). In addition, the reproducibility of 4DCT-based ventilation
imaging has yet to be investigated. The reproducibility of 4DCT-based ventilation
imaging is highly dependent on the reproducibility of the 4DCT captured
breathing cycle. We hypothesize that global defects investigated in this study
would appear consistently in the same region regardless of the captured breathing
cycle; however, future work is needed to investigate the reproducibility of 4DCTbased ventilation maps. The process of calculating ventilation images from 4DCT
data is still being refined and is not yet fully automated; thus, user input is
required throughout the calculation process. In our study, we registered weekly
ventilation images by registering the corresponding exhale CT datasets. For
patients that showed a reduction in the GTV throughout treatment, the deformable
image registration algorithm enlarged the weekly tumor volume in an attempt to
match the image to the original pre-treatment tumor volume. The week to week
image registration spatial errors may not impact the global ventilation
characteristics investigated in our study; however, future work that attempts to
perform a pixel by pixel analysis should consider the week to week spatial image
registration errors due to tumor volume reduction. Our data set consisted of
images taken throughout the course of radiation therapy. However, radiation
effects (to normal tissue and tumor) can occur weeks or months after radiation
therapy. In future work, we plan to perform a similar analysis on data that
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includes 4DCT images acquired several months after the completion of radiation
therapy. Finally, in order to completely evaluate lung function it would be
preferable to have ventilation as well as perfusion information.
Conclusions
In the current study we present a unique dataset of 4DCT-based ventilation
images calculated weekly for 6 lung cancer patients undergoing radiation therapy.
For our patient cohort, we did not find a consistent pattern of ventilation change as
a function of radiation dose. Furthermore, we determined that pretreatment
ventilation was significantly lower for lobes that contained tumors, particularly in
cases where the tumor was occluding a central airway. The weekly lobe
ventilation data indicated that when tumor volume is reduced the ventilation will
increase and when there is no change in the thoracic anatomy, we did not measure
a ventilation change.

Further developments mitigating the uncertainties and

improving the robustness of the calculation method along with more data points
will enable us to make stronger and more local conclusions about changes in
ventilation for patients undergoing radiation therapy.”
Pre-treatment ventilation study
Methods
The purpose of this study was to incorporate ventilation-based functional
information into the modeling of radiation pneumonitis and determine whether
incorporating the functional information could improve the fit of our model. Initially, 120
patients from the MD Anderson NSCLC patient database (described in the Patient
Database section) were selected for this study. These were the patients that contained
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data from 4DCT simulation. Upon reviewing the 4DCT images, we decided to exclude 45
patients because of the poor quality of the 4DCT images. The poor quality was due to
motion artifacts or because images did not encompass the entire volume of the lung. As a
result, we had 4DCT data for 75 patients from our 1999-2005 patient database. In order to
increase the number of patients in our study, we selectively chose 17 patients from a
database that was being accumulated for 2006. This NSCLC database contained similar
information to the 1999-2005 database but contained patients that were treated in 2006
(rather than 1999-2005). We selectively chose patients to include a majority of patients
that went on to develop severe (grade 3-5) radiation pneumonitis. The rationale and
limitations of selectively choosing patients will be addressed in the discussion section.
For each patient we used the pre-treatment 4DCT data to calculate a pre-treatment
ventilation image using the methodology previously described. We normalized the data
by converting each ventilation image to a percentile image. Each patient’s treatment plan
was restored into the treatment planning system providing information about the dose
distribution. By definition, the ventilation image is defined on the same coordinate system
as the exhale phase (50%) of the 4DCT dataset. The exhale CT phase is defined on the
same CT coordinate system as the CT data set (average CT dataset) used to calculate
dose. Therefore, the ventilation image and the dose distribution were inherently
registered.
For each patient we calculated a DVH and a dose-function histogram (DFH). The
DFH was calculated in the manner proposed by Marks et al (61). The first step in
computing the DFH was to group the data into dose bins and for each bin add the
normalized ventilation values corresponding to that dose bin. The bins were normalized
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by dividing each bin by the sum of all bins in the histogram. A cumulative DFH was then
calculated by summing the fractional ventilation of all the dose bins greater than or equal
to the dose of each bin. In addition we calculated a MLD and a functionally weighted
mean lung dose (fMLD). The fMLD was calculated by multiplying each dose voxel by
the ventilation value of that voxel. Furthermore, we calculated an effective dose (Deff) and
the functional effective dose (fDeff ) using Equation 3 with the n parameter set equal to
0.5. Although it has been established that the volume parameter (n) is not different from 1
for the lung (6) we decided to investigate different values for n because there has been no
precedent set when investigating dose and ventilation relationships in the lung.
We grouped the data into 2 categories: patients who experienced severe (grade 35) radiation pneumonitis and patients who did not experience severe pneumonitis (grade
0-2). We compared the MLD, fMLD, Deff, and fDeff, values between the 2 groups using a
two-sample ttest and a ranksum test (29). Furthermore, we incorporated the ventilationbased functional information into a predictive risk model. We incorporated the
ventilation-based functional information into the model described by Equation 10. The
model described in Equation 10 is the same model that was used for the spatial study,
except in this instance the weighting values (wi) were defined by the ventilation image. In
other words, the weighting will not be defined by a spatial weighting scheme but rather
by a ventilation weighting scheme. Similar to the methodology used for Specific Aim 1,
we used the likelihood ratio test to compare the fit of the model that incorporates dosevolume to the fit of the model that incorporates dose-volume and ventilation-based
functional information. The likelihood ratio test will determine whether adding in an
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additional parameter (ventilation-based functional information) can significantly improve
the model fit to the data.
Results
Individual patient examples of a dose distribution, ventilation map, DVH, and
DFH are shown in Figure 19 and Figure 20. The example patient shown in Figure 19 had
a mean lung dose of 22.9 Gy and did not develop severe radiation pneumonitis. The dose
distribution and

Figure 19: Dose distribution (A), ventilation image (B), and DVH and DFH example for
one patient. This patient provides an example where dose was delivered to the nonfunctional portions of the lung and where the DFH is lower than the DVH. This patient did
not develop severe radiation pneumonitis
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Figure 20: Dose distribution (A), ventilation image (B), and DVH and DFH example for
one patient. This patient provides an example where dose was delivered to the functional
portions of the lung and where the DFH is greater than the DVH. This patient went on to
develop severe radiation pneumonitis.
ventilation image (Figure 19) illustrate that this patient received the majority of dose to
the non-functional and non-ventilation portions of the lung. As a result, the DFH appears
well below the DVH. By contrast, the example patient shown in Figure 20 received a
MLD of 23.2 Gy and did go on to develop severe radiation pneumonitis. The dose
distribution and ventilation image indicate that the patient received dose to highly
ventilated portions of the lung. As a result, the DFH appears greater than the DVH.
Although the MLD and the DVHs of these patients are similar, the difference between the
spatial dose and function combination of the 2 patients is highlighted using the DFH.
A scatter plot showing the fMLD versus the MLD is shown in Figure 21. This
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Figure 21: Scatter plot showing the variable change from MLD to ventilation weighted
MLD (fMLD). A linear fit to the data is shown as a black line. The pneumonitis rate is
22.4% above the line and 12.8% below the line.
graph highlights the change of variable in going from the MLD to the fMLD. It is
important to note that the scatter plot appears spread out and the data does not lie on a
straight line. If the data were to lie on a straight line that would indicate that weighting
the dose with the ventilation values would not add any extra information in addition to
the MLD. Furthermore, a linear fit to the data is shown in Figure 21. The pneumonitis
rate above the line is 22.4% and 12.8% below the line. This indicates that the fMLD helps
separate the toxicity data better than the MLD.
The box plot (Figure 22) shows that the fMLD was higher for patients that
developed severe radiation pneumonitis. However using a two-sided ttest the difference
between the 2 groups was not significant (p = 0.251). Furthermore, there was no
difference between the 2 groups in the MLD, Deff (using n = 0.5), and fDeff (using n = 0.5),
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using either a ttest or a ranksum test (Table 14). When the model parameters were
determined for the dose-volume model (Equation 4) the m and TD50, values were
calculated to be 0.76 and 70.66 respectively. The parameters for the dose-volume and
functional model (Equation 10) were calculated to be 1.38 x 106, 0.61, and

Figure 22: Box plot comparing the ventilation weighted MLD between the pneumonitis
and non pneumonitis group. As expected the group that developed pneumonitis had
higher ventilation weighted doses than the group that did not develop pneumonitis.

Dose-volume
metric
MLD
fMLD
Deff (n=0.5)
fDeff (n=0.5)

ttest

ranksum test

0.585
0.251
0.350
0.118

1
0.372
0.788
0.238

Table 14. Significance values for the various dose-volume and ventilation weighted
dose-volume metrics that were investigated. The significance values indicate a
difference in the metric between the group that developed severe pneumonitis and the
group that did not develop severe pneumonitis.
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6.04 x 104, for the m, TD50, and C values respectively. Using the likelihood ratio test the
difference in fits of the two models was not found to be significant (p = 0.312).
Discussion
We have combined some novel techniques along with the methods proposed by
Nioutsikou et al (42) and Miften et al (41) to incorporate ventilation-based functional
information into the modeling of radiation pneumonitis. The individual patient examples
(Figure 19 and Figure 20), scatter plot (Figure 21), and box plot results are promising.
The patient examples illustrate how the combination of dose and function information can
lead to a better understanding of the effect of radiation on the normal lung. The scatter
plot shows that converting from MLD to a fMLD will separate the data, meaning that the
two metrics are not equivalent. Furthermore, using a linear fit, the scatter plot
demonstrated graphically that the fMLD is a better predictor of pneumonitis than the
MLD. As expected, the box plot indicates that the fMLD is greater for patients that
developed severe radiation pneumonitis than for patients that did not develop severe
radiation pneumonitis. However, using statistical analysis and maximum likelihood
methods the results were not shown to be significant. Based on the promising initial
results we believe the statistical results can be improved by incorporating more patients in
future work.
The current study contained 96 patients; while this is consistent with the number
of patients in similar studies (43, 78, 79), an important question to address is how many
patients would be needed to find a statistically significant result. In order to determine
how many patients would be needed we performed a sample size simulation. The idea of
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the simulation was to simulate data based on existing results, perform the statistical test
we were interested in and calculate how many samples are needed for a power ratio of
80%. The power ratio is defined by the ratio of the number of successful samples to the
total number of samples. Successful samples could imply statistical significant results at
the p = 0.05 level or cases where a certain p value is larger than another p value. The first
step was to simulate the pneumonitis data. Out of the entire patient population we decided
to simulate a 50% pneumonitis rate. While 50% is not representative of a true
pneumonitis rate, an assumption is made that we are able to selectively pick our data.
Then for the pneumonitis and non-pneumonitis groups we simulated MLD and fMLD.
The MLD and fMLD were generated for the pneumonitis and non-pneumonitis group
using a normal distribution and mean and standard deviation values calculated from our
existing data. For example, the simulation of the MLD was simulated with a mean of
20.58 and a standard deviation of 4.55 (Figure 23). Once all of the MLD and fMLD
values were simulated we performed a ttest comparing the MLD amongst the
pneumonitis and non pneumonitis group and a ttest comparing the fMLD among the
pneumonitis and non pneumonitis group. We calculated the power as the number of times
the p value for the fMLD ttest was smaller than the p value for the MLD ttest normalized
by the total number of simulation. In order to reach 80% power, 680 simulations were
needed. It is also possible to perform a power calculation using regression analysis with a
probit link. When we performed a regression analysis with the MLD and fMLD, 610
simulations were needed for a power of 80%. It should be noted that the regression
analysis is not the ideal test to use because the pneumonitis events are being artificially
selected. However, it is promising that both statistics needed around 650 patients for a
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power ratio of 80%. Although there are assumptions made in the simulation that could
affect the sample size calculation, the exercise underlines that a much larger sample size
would be needed to prove statistical significance.

Figure 23: A histogram of the simulation results for the entire population MLD. The
histogram confirms that the simulation mean and standard deviation of the normal
distribution were 20.58 and 4.55 resepctively.
Because 4DCT-based ventilation imaging is a new method of calculating lung
function, most of the literature has focused on the methodology to calculate ventilation
and as a result there are no papers relating ventilation-based functional information to
radiation pneumonitis. Yaremko et al (59) demonstrate that it is possible to reduce highly
ventilated portions of the lung using IMRT; however, this is mostly a methodology paper
and does not relate ventilation to clinical symptoms. Because of readily available data,
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most of the literature has focused on incorporating SPECT-based perfusion imaging into
the prediction of thoracic radiation toxicity. Several studies have tried to correlate
SPECT-based perfusion changes with pulmonary function test (PFT) data. Studies by Fan
et al (78) and Ma et al (63) found significant results in correlating perfusion changes with
PFT changes; however, the studies noted modest correlation coefficients (0.18 – 0.30).
Lind et al (79) incorporated dosimetric and perfusion information and used receiver
operating characteristic (ROC) analysis to evaluate the predictive abilities of each metric.
They report that the models that incorporated dose and perfusion were best correlated
with pneumonitis; however, they report an area under the ROC curve in the range of 0.610.72. These values are not an indicator of a strong relationship between dose and
perfusion with radiation pneumonitis. Seppenwoolde et al (43) report that the overall
mean perfusion-weighted lung dose and mean perfusion-weighted regional doses to the
posterior, inferior, ipsilateral, and central regions were associated with radiation
pneumonitis. They also report that the doses to the entire lung and regional doses (not
accounting for perfusion) were correlated with pneumonitis. In this instance, it is difficult
to distinguish between correlations caused by dose and correlations caused by dose to
functional portions of the lung. Kocak et al (40) developed a model to incorporate dose
volume and perfusion into the prediction of pneumonitis and applied their model to an
independent data set. They report that their model was not able to accurately segregate
patients into high and low risk groups. Our data is in line with the results proposed in the
literature. Both our results and those of others (40, 43, 63, 78, 79) provide some
promising initial findings; however, the data does not turn out to be statistically
significant in most cases. There are several possible explanations. One explanation for the
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lack of statistical significance is the number of patients in the studies. Specifically, the
number of patients developing radiation pneumonitis is low. With more patients, the
number of patients developing radiation pneumonitis would increase and the statistical
metrics would improve. Our sample size simulation suggested that around 600 patients
would be needed for significant results; however, most of the studies are limited to
around 100 patients. Another possible explanation is the lack of biological understanding
of the relationship between lung function and symptomatic toxicity. There are several
metrics and imaging modalities that have been used to describe lung function. These
include: PFT, perfusion, ventilation, diffusion, and inflammation. There is no clear
conclusion in the literature that any of the metrics (or any combination of the metrics) can
be used to completely describe lung function and lung damage. The current study and
many of the studies in the literature investigate the relationship between one metric and
symptomatic radiation pneumonitis. It is possible that a combination of the imaging
modalities (for example ventilation, diffusion, and perfusion) is needed to completely
describe lung function and to demonstrate the relationship between lung function and
symptomatic toxicity.
There were several limitations to our study. As stated previously, we believe with
more patients the statistics of our study could be improved. However, we do not believe
the number of patients in this study was unreasonably low. We analyzed 96 patients for
this study, by comparison Lind et al (79) had 166, Fan et al (80) had 96, and
Seppenwoolde et al had (43) 106. In order to increase the number of pneumonitis events
in our study we manually selected a portion of our data. Because some of the data were
manually selected, the pneumonitis rate is not representative of the patient population at
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MD Anderson and therefore the modeling parameters cannot be compared with those
published in the literature. However, because the likelihood ratio test calculates an
improvement in model fit to the data, the significance value stated is valid, despite the
manually selected patient population. Furthermore, the ttest and ranksum statistics
comparing the MLD and fMLD for the pneumonitis and non-pneumonitis group are valid
as well, despite the manual selection of the data. All of the uncertainties associated with
calculating ventilation images discussed in the Serial Ventilation study apply to this
section as well. Particularly is worth noting that the ventilation images are sensitive to the
particular breathing cycle captured by the 4DCT. We normalized our data by converting
the ventilation images to percentile images. We normalized the data in this manner
because this was the method previously used in the literature (59, 65, 73) and because it is
the method that best mitigates the uncertainties associated with calculating 4DCT-based
ventilation. However, there are other possibilities for normalizing the data. For example,
it is possible to normalize the data using a universal maximum ventilation value or by
using the maximum voxel value in a particular image. The magnitude of the ventilation
images is dependent on the shallowness and depth of the breathing cycle captured by the
4DCT. Certain patients may not take as large a breath and therefore their ventilation
values would be smaller than those of patients who took a deeper breath. This would be
equivalent to administering differing amounts of radionuclide in SPECT exam. Patients
may have different magnitude values of their ventilation image that may not necessarily
be associated with function but rather the amplitude of the breathing captured by 4DCT.
As a result, we believe it is best to normalize the ventilation images to themselves (as
opposed to using a population based normalization value). Furthermore, by using the

81
percentile image we mitigate the effect of the maximum voxel value on the rest of the
image, which is important because the maximum voxel ventilation values are often the
most prone to the uncertainties associated with calculating 4DCT images. In this study,
we attempted to associate ventilation with lung function and symptomatic pulmonary
toxicity. As mentioned previously, lung function can be defined by ventilation, perfusion,
diffusion, inflammation, and PFT data. Therefore, in future work it would be informative
to combine these modalities to better determine lung function and improve the prediction
for radiation pneumonitis. In addition, as the patient database grows, it would be
informative to correlate lung function (as measured by ventilation) by more specific
patient groups according to: age, PFT data, and prior lung disease.
Conclusions
In this study we used pre-treatment 4DCT-based ventilation images to determine
lung function and help predict for radiation pneumonitis. The hypothesis of the study is
rejected because we were not able to achieve a significant improvement in model fit by
incorporating ventilation-based functional information. Although we were not able to
achieve a significant improvement in model fit with our 96 patient database, we show
some promising results indicating that ventilation imaging can provide useful information
about lung function in lung cancer patients. We believe more patients are needed to
demonstrate a significant relationship between dose to highly ventilated portions of the
lung and symptomatic radiation pneumonitis.

82
Specific Aim 3 – Personalized prescription study
Introduction
Dose escalation trials have been performed that report promising results for lung
cancer patients receiving radiation therapy. Dose escalation trials can broadly be
categorized into 2 types of dose escalation schemes: randomized dose escalation and dose
escalation using dose-volume metrics. The study by Perez et al (11) provides an example
of a randomized dose escalation scheme where patients get randomized to a treatment
arm and depending on the treatment arm they receive a certain amount of dose to the
tumor. More recent studies have employed dose escalation schemes that are based on
dose-volume metrics. For example, Bradley et al (16) escalated doses based on V20 while
Belderbos et al (46) and Van Baardwijk et al (48) escalated dose based on MLD. The
group at the University of Michigan went a step further and used NTCP models to
calculate effective volume (Veff) and determine the dose based on Veff (45). It should be
noted that although the study explicitly incorporated NTCP modeling into the
determination of dose, the NTCP model was based solely on dose-volume metrics.
In addition to dose volume, researchers have attempted to incorporate other
patient and clinical factors as predictive factors for severe radiation pneumonitis. As
noted earlier, studies have proposed a correlation between radiation pneumonitis and
chemotherapy (35), performance status (36), smoking status (37), tumor location within
the lung (32, 33, 39), and functional status of the lung (40-42). One of the factors that has
been investigated in relationship to radiation pneumonitis has been genetic information in
the form of SNPs (38). SNPs are a type of biomarker and are considered to be DNA
sequence variations. Recent research interest has been focused on identifying SNPs
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associated with different inflammatory cytokines (signaling proteins). Yuan et al (38)
showed that the CT/CC genotypes of the cytokine transforming growth factor B1
(TGFB1) gene were associated with a lower risk of radiation pneumonitis. In a similar
study, Anscher et al (81) evaluated 73 patients that were treated with definitive
radiotherapy and determined that TGFB1 appeared to be a useful means to identify
patients at low risk for developing radiation pneumonitis. It should be noted however that
the data is not consistent. For example, the results reported by De Jaeger et al (82) did not
confirm that increased levels of TGFB1 were a risk factor for developing pneumonitis.
Other SNPs have also been investigated. Fogarty et al (83) studied the SNP MC1R and
found that it was associated with unexpectedly high severe acute reactions to radiation
therapy. In a recent study (84), our group incorporated SNPs as biomarkers into a
predictive LKB NTCP model. We analyzed 143 patients with NSCLC treated definitively
with radiation therapy. The study genotyped 15 potentially functional SNPs and found
that TGFB073 = TT, XRCC_NIH = WW, and VEGF4039 = CT/TT, were selected as
adverse risk factors. In other words, patients with the above mentioned genotypes of the 3
SNPs were at a greater risk for developing radiation pneumonitis.
The next logical step in dose escalation studies is to prescribe dose based on
NTCP models. Specifically, using NTCP models that are further individualized because
they incorporate additional factors bedsides dose-volume. By using NTCP models that
account for patient and clinical factors, the derived lung dose limit and subsequent target
dose prescription can become personalized to the patient, rather than being population
based. The concept of personalizing a lung dose limit to individuals is an idea that certain
thoracic physicians may do already. For example, when deciding how much dose can
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safely be delivered to the lung, physicians may consider the patient’s chemotherapy
status, surgery status, or PFT scores. However, as additional factors are found to be
associated with radiation pneumonitis a more rigorous approach is needed. The concept
of personalizing the lung dose limit and the prescription dose are demonstrated in the
current study. We perform a virtual dose prescription trial where the prescription is
determined using an individualized lung dose-volume constraint that is calculated using a
NTCP model. We will use a model that is composed of dose-volume and genetic (SNP)
information. Our hypothesis is that the median difference between the model-determined
prescription and the clinically achieved prescription will be greater than a clinically
significant threshold of 5 Gy.
Methods
The patient database used for this study was taken from our previous work (84).
The study published by Liao et al (84) contained 143 patients; however, we were only
able to de-archive 141 patients into the treatment planning system. Therefore, 141
patients were used for this simulation. The patients had a diagnosis of NSCLC and were
treated with definitive radiation therapy both with and without concurrent chemotherapy.
The distributions of genotypes for each SNP are shown in Figure 24. Each genotype was
well represented within the patient population except for the TT genotype of the VEGF
SNP (which was represented by 3 patients).
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Figure 24: Distribution of genotypes for each
SNP. The red bars represent genotypes that
were selected as adverse risk factors for
radiation pneumonitis and the blue bars
represent genotypes that were not a risk
factor for developing radiation pneumonitis.

The first step was to mathematically describe the model that would be used to
determine the personalized lung dose limit. To incorporate dose-volume and SNP
information we used the LKB NTCP formulation described in Equations 1 and 7. The
TD50 and m values that were fit to the data were determined to be 36.6 Gy and 0.381
respectively. The SNP data were incorporated as DMF factors. The total DMF (DMFT)
was defined as
Equation 12
where DMFXRCC, DMFTGFB, and DMFVEGF where the DMFs for the individual SNPs. For
patients that had a genotype of WW for the XRCC SNP the DMFXRCC = 0.681, for
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patients that had a genotype of CT or TT for the VEGF SNP the DMFVEGF = 0.733, and
for patients that had a TT genotype for the TGFB SNP the DMFTGFB = 0.783. If the
patients did not have the genotypes described above for the 3 SNPs, then their DMFs
were set to 1. These were all parameters that were fit to our patient database in the
previous study (84). Each DMF factor can theoretically be thought of as effectively
reducing the TD50 parameter in Equation 7. As the TD50 parameter gets reduced the dose
response curve is shifted to the left, and for the same MLD there is a greater risk of
pneumonitis, or conversely, a lower MLD is needed for the same risk of pneumonitis.
Therefore, each selected genotype moves the curve to the left and can be theoretically
thought of as increasing a patient’s risk for radiation pneumonitis. The NTCP curves
described in Equations 1, 7 and 12 are displayed in Figure 25.
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Figure 25: NTCP curves for different combination of genotypes for the 3 SNPs
investigated (XRCC, TGFB, VEGF). Knowing each patient’s genotype allows for each
patient to be placed on one of the curves shown..
There were 8 total curves in the plot because there are 8 different possible combinations
of DMFXRCC, DMFTGFB, and DMFVEGF, resulting in 8 different possibilities for the DMFT.
Conceptually, we know the genotype for each patient for the 3 SNPs (XRCC, TGFB, and
VEGF) and therefore can determine which one of the 8 curves shown in Figure 25 the
patient falls on. The next piece of information needed for the personalized lung dose limit
is the acceptable complication probability. In theory, this would be the clinically agreed
upon radiation pneumonitis complication probability and would be determined based on a
clinical decision balancing tumor control and normal tissue toxicity. For the current
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study, we simulated several different scenarios. We simulated a pneumonitis rate of 22.6
% because that was the true complication rate in our dataset. We also simulated
complication probabilities of 20% and 25% to study the dependence of the prescription
change on the complication probability. Once we know which curve each patient falls on
and have an agreed upon complication probability we can determine a personalized dose
limit for each patient (Figure 26).

Figure 26: Three example NTCP plots relating MLD and radiation pneumonitis
complication probability. The plot illustrates that for 3 different patients with 3 different
genotypes, using a complication probability of 22.6, the MLD limits would be personalized
and different for each patient.
For example, for a complication probability of 22.6% it is possible to have a patient with
a SNP genotype that calls for a MLD limit of 10 Gy, 15 Gy, or as much as 26 Gy (Figure
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26). The MLD limit is “personalized” because it is based on each individual patient’s
genotypical expression of the 3 SNPs. In the current approach, each patient has their own
MLD limit (although in this study 8 different MLD limits exist), as opposed to a universal
MLD limit that is applied to the entire patient population. In addition to the model
derived lung dose limit, we applied treatment planning parameters to the spinal cord,
esophagus, and the heart (Table 15). For the spinal cord we used a maximum dose
Organ

Limit

Lung

Model
determined

Spinal
Cord

Dmax < 50 Gy

Esophagus

V60 < 50%

Heart

V50 < 50%

Table 15. Dose-volume limits used for the virtual simulation study.
of 50 Gy, for the esophagus we used a V60 of 50%, and for the heart we used a V50 of
50%. These are in line with the treatment planning parameters used in our clinic.
The DVH and dose-volume parameters for each patient’s clinically used plan
were exported. It is important to note that at this point of the study, only the patient’s
clinical plan was used. There was no re-planning or re-contouring, and we used the same
beam arrangement and design as was used for the clinically delivered plan. We applied
the model-determined MLD limit as well as the other treatment planning parameters to
the dose-volume parameters exported from the patient’s clinical plan and determined if
we could escalate the dose or if the dose needed to be lowered. If all of the clinical
parameters fell below the model-determined MLD limit and the other organ limits, then
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we could increase the prescription dose. Conversely, if some of the parameters exceeded
the model-determined MLD limit or any of the other applied limits, then the prescription
dose was lowered. The next step was to determine the quantity by which the dose needed
to be escalated or de-escalated. To calculate the dose escalation or de-escalation, we
calculated a ratio of the patient’s clinical parameters to the set treatment planning limits.
It should be noted that while the MLD and the spinal cord max dose can be calculated as
a linear scaling, in order to determine a ratio for the volume parameters (used for the
esophagus and heart) the DVH needs to be used. For example, to calculate the possible
dose escalation or de-escalation due to the esophagus, the ratio of 60 Gy to the D50 is
taken. A graphical representation of how the ratio of doses was calculated using the DVH
is shown in Figure 27.
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Figure 27: An example of how an esophagus DVH is used to calculate the change in
dose needed to change the V60 to 50%. First the D50 is identified, then the ratio of 60 Gy
divided by D50 is taken as the amount the dose needs to be escalated (or de-escalated in
some cases) to achieve a V60 of 50%. The theoretical movement of the DVH using a
dose escalation ratio calculated by the method above is shown in green. For this patient
example, the dose can be escalated by 600% based on the esophagus. In this patient
example, the prescription dose would likely be limited by another normal tissue organ.
Once all the ratios were calculated, for each individual patient, the organ with the
minimum ratio was taken as the dose limiting organ. For example, if the dose could be
escalated by 6% according to the lung limit and 15% according to the spinal cord limit,
then the lung would be the dose-limiting organ and the dose could only be escalated by
6%. Similarly for dose de-escalation, if the dose had to be lowered by -6% according to
the lung limit and by -15% according to the spinal cord, then the spinal cord would be the
dose limiting organ. Once the dose-limiting organ was determined, the dose escalation or

92
de-escalation scheme dictated by that organ was applied to the prescription dose as well
as the other dose-volume parameters. We then noted the difference in the modeldetermined prescription dose and the clinically used prescription dose. In other words, if
the model-determined prescription was greater than the clinically achieved prescription,
then according to the model we should dose escalate for that particular patient, if the
model-determined prescription was lower than the clinically used prescription, then
according to the model the dose needed to be reduced. In summary, we scaled the
prescription dose for each patient according to normal tissue constraints. We used
conventional dose-volume constraints for the spinal cord, esophagus, and heart, and a
personalized MLD limit determined from a NTCP model. We studied the difference in
the model-determined prescription dose and the clinically used prescription dose. The
change in prescription was investigated as a function of the selected complication
probability. We also noted the differences between the model-determined MLD limit and
the clinically used MLD limit. Furthermore, in order to gain an understanding of the
dose-limiting organ for the entire patient population, we noted the dose-limiting organ for
each individual patient. For 31 of the patients in the study the clinically used dose-volume
values for the spinal cord, esophagus, and heart, exceeded the dose-volume limits that we
imposed for the study (prior to the model-determined MLD limit being applied). This
occurred because the clinician made a decision to exceed dose-volume constraints in
favor of better tumor control. To investigate the effect of having these patients in our
study, we performed a simulation where the patients that had exceeded dose-volume
constraints before the MLD limit was applied were excluded.
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It is instructive to go through the personalized dose prescription process for an
individual patient example. The patient’s dose distribution is shown in Figure 28 and the
dose-volume parameters, limits, and ratios are shown in Table 16.

Figure 28: Dose distribution
for the patient used in the
example calculation.
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Prescription
(Gy)

MLD
(Gy)

Cord
max (Gy)

Esophagus
V60 (%)

Heart
V50 (%)

60

23.6

43.2

37.5

26.1

Limits

24.9

50

50

50

Ratio

1.06

1.16

1.09

4.2

24.9

45.8

49.7

23.5

Clinical

Modelgenerated
parameters

63.6

Table 16: A single patient example of the procedure used to determine the modelgenerated prescription. The table shows the patient’s clinical parameters, the
applied dose volume limits, the ratio between the limits and the clinical
parameters, and finally the model-generated parameters.
This particular patient received 3D-CRT with a prescription dose of 60 Gy. The MLD for
the patient was 23.6 Gy, the esophagus V60 was 37.5%, and the heart V50 was 26.1%. The
patient had a genotype of WP for the XRCC SNP, CT for the TGFB SNP, and CC for the
VEGF SNP, corresponding to DMFs of DMFXRCC = 1, DMFTGFB = 1, and DMFVEGF =
0.733, for a DMFT = 0.733. Using Equations 1 and 7, along with a DMFT = 0.733 and a
complication probability of 20%, the personalized model-determined MLD limit for this
patient is 24.9 Gy. The other limits are set as stated above; 50 Gy for the cord max dose,
50% for the esophagus V60 and 50% for the heart V50. For this patient, all the dosevolume parameters for the clinically used plan fell below the set limits; therefore, the
dose could be escalated. Using a linear relationship, based on the MLD and spinal cord,
the dose can be escalated by 6% and 16% respectively. Using the DVH, the dose can be
escalated by 9% according to the esophagus and 320% using the heart. The minimum
ratio for this patient is 6%; therefore the dose limiting organ will be the lung. The 6%
dose escalation scheme is applied to the prescription dose as well as the other dose-
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volume parameters. The resulting prescription dose is 63.6 Gy, while the new MLD is
24.9 Gy, the new spinal cord maximum dose is 45.8 Gy, the new esophagus V60 is 49.7%
and the new heart V50 is 23.5%. The metric of interest for this study was the difference
between the model generated prescription dose and the clinically achieved prescription
dose, which for this patient is calculated to be +3.6 Gy. As expected, the MLD value is
maximum, while the other dose-volume parameters don’t reach their maximum allowable
values.
Results
A histogram of the difference between the model generated MLD and the
clinically achieved MLD for all patients is shown in Figure 29. Patients that fell to the left
of zero are patients for whom the model predicted a lower dose than what was given
clinically. The patients to the right of zero are patients that the model predicted could
have received a higher MLD than was given clinically. For example, patients in the 20 Gy
bin in Figure 29 are patients that could have theoretically received an increase of 20 Gy to
their MLD. As expected, the most frequent occurrence is a small change between the
model-generated MLD and the clinically achieved MLD.
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Figure 29: A histogram of the difference between the model-generated MLD and the
clinically achieved MLD.

A histogram of the difference in the model-generated prescriptions and the
clinically achieved prescriptions is shown in Figure 30. The patients to the left of zero are
the patients for who the model dictated that the prescription dose is reduced, while the
patients to the right of zero are the patients for whom the model predicted that the doses
could be escalated. Although there are 35 patients in the 0 Gy bin, the histogram shows
that for most patients, there would be a change if the prescription was based on a model.
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Figure 30: A histogram of the differences between the model-generated prescriptions
and the clinically achieved prescriptions.
The mean, median, and range of the change in prescription doses are shown in Table 17.
Clinical
Rx (Gy)

Model Rx
(Gy)

Model Rx – Clinical
Rx (Gy)

Absolute Rx
Difference (Gy)

Mean

65.4

62.7

-2.7

10.0

Median

63.0

63.7

-1.7

6.0

Range

60.0-72.0

40.0-100.0

-29.6 – 37.0

0-37.0

Table 17: The overall clinically achieved prescription, model generated
prescription, and changes in prescription for the entire patient population.
The average difference between the model generated plans and the clinically used plans
was a reduction of -2.7 Gy (with a median value of -1.7 Gy). The range of changes in
prescription include a dose reduction of 29.6 Gy and a dose escalation of 30 Gy. In order
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to quantify the change in prescription for each patient, regardless of the sign, we
calculated the absolute value in the changes in prescription. The mean and the median
absolute changes were 10 Gy and 6 Gy respectively, suggesting that for most patients,
using the model to generate a prescription dose will result in a change of at least 6 Gy in
either direction (dose escalation or de-escalation). The mean and median changes in
prescription are both negative (-2.7 and -1.7 respectively from Table 17), implying that
overall the model-predicted doses were lower than the clinically achieved doses. This
occurred because for 31 patients, the dose-volume parameters for the clinically used plan
exceeded the limits that were set for this study (prior to applying the model-determine
MLD limit). Excluding these patients, the histogram reveals (Figure 31) that fewer
patients appear to the left of zero, or fewer patients for whom the dose needs to be
reduced.
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Figure 31: A histogram of the difference between the model-generated prescription dose
and the clinically achieved prescription dose for the reduced patient population. Patients
were excluded if their clinical dose-volume metrics for the spinal cord, esophagus, or
heart exceeded the set limits prior to dose escalating or de-escalating.

Furthermore, Table 18 shows that the mean and median changes in prescription were -0.7
Gy and 1.4 Gy, respectively, for the reduced patient cohort.

100

Clinical Rx
(Gy)

Model Rx
(Gy)

Model Rx –
Clinical Rx (Gy)

Absolute Rx
Difference (Gy)

Mean

65.4

65.1

-0.7

10.1

Median

63.0

64.5

1.4

5.8

Range

60.0-72.0

40.0-100.0

-29.6 – 37.0

0-37.0

Table 18: The overall clinically achieved prescription, model generated
prescription, and changes in prescription for the reduced patient population.
Patients were excluded if their clinically achieved dose-volume parameters for the
spinal cord, esophagus, or heart exceeded the limits set for the study (prior to
applying the model-determined MLD limit).

These values are closer to zero than the values shown in Table 17. It is also important to
point out that when the absolute value of the changes is taken for the reduced patient
cohort, the median change for the entire patient population is 5.8 Gy, indicating that for
most individual patients using the model will result in a change (dose escalation or deescalation) of at least 5 Gy.
The histogram of the change in prescription according to the presence of
pneumonitis is shown in Figure 32.
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Figure 32: A histogram of the difference in prescriptions according to the presence or
absence of severe pneumonitis.

The patients that developed severe radiation pneumonitis are shown as a separate group in
Figure 32. As expected, most of the patients that developed radiation pneumonitis appear
to the left of zero, indicating that for those patients the model predicted that the
prescription doses needed to be reduced.
The personalized model-determined lung limits (and subsequently prescription
values) are highly dependent on the chosen complication probability. We investigated the
effect of choosing different complication probabilities on the prescription results. In
addition to the nominal complication probability value of 22.6%, we chose to investigate
complication probabilities of 20% and 25%. The histogram shown in Figure 33 displays
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the change in prescription for the 20% complication probability simulation and the 25%
complication probability simulation. As expected, the simulation using the 25%
complication probability had fewer patients with a negative change in prescription and
more patients with a positive change in prescription than the simulation using the 20%
complication probability. These results are quantified in Table 19. The mean and median
changes in prescription are higher for the 25% complication probability simulation than
for the 20% complication probability simulation. These data suggest that overall, as the
complication probability is increased the change in prescription will be skewed towards
an increase in dose prescription for each patient.

Figure 33: A histogram of the difference between the model-generated prescription and
the clinically achieved prescription displayed according to different complication
probabilities.
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Clinical
Rx (Gy)

NTCP = 20%
Model Rx –
Clinical Rx (Gy)

NTCP = 25%
Model Rx – Clinical
Rx (Gy)

Mean

65.4

-0.3

2.5

Median

63.0

-2.9

0.1

Table 19: Mean and median change in prescription for the 20% complication
probability simulation and the 25% complication probability simulation.
The dose limiting organs for the simulation using the 22.6% complication
probability are shown in Table 20. As expected, the model-derived lung dose limit was
the most frequent dose limiting organ. The lung limit was the limiting factor for 54% of
patients, the cord max dose was the limit for 40% of patients, the esophagus was the limit
for 4% of patients, and the heart was the limiting organ for 2% of patients.
Dose-volume limit
Model generated lung
limit
Cord
Esophagus
Heart

Number of
patients (%)
77 (54%)
55 (40%)
6 (4%)
3 (2%)

Table 20: Data showing the dose limiting organ for the simulation using the 22.6%
complication probability.
Table 21 shows the dose limiting organ for the simulations using the 20% complication
probability and the 25% complication probability. The model generated lung limit was
the limiting factor for 59% of patients for the simulation where the complication
probability was set at 20% and 50% for the simulation where the complication probability
was set at 25%. As the complication probability is allowed to increase and the lung
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planning limit is relaxed, the model generated lung parameter becomes a less frequent
limiting factor.

Dose-volume limit
Model generated lung
limit
Cord
Esophagus
Heart

NTCP = 20 NTCP = 25
Number of Number of
patients (%) patients (%)
83 (59%)
50 (35%)
5 (4%)
3 (2%)

70 (50%)
60 (42%)
8 (6%)
3 (2%)

Table 21: Data showing the dose limiting organ for the simulation using the 20%
complication probability and the 25% complication probability.
Discussion
The most significant finding of the virtual simulation is that for individual
patients, using a model-generated personalized MLD limit would result in a different
prescription than what was used clinically. The histogram of the difference in the MLD
underlines that for individual patients the model based on SNPs predicts a different MLD
to the patient than was clinically delivered. When the personalized MLD limit is used to
determine a model-based prescription, the histogram demonstrates that for individual
patients a change will result in the prescription dose. Furthermore, regardless of the
complication probability used, the median change in the model-determined prescription
and the clinically achieved prescription is over a clinically significant value of 5 Gy
(Table 17, 18, 19). If the SNP findings are verified in independent patient cohorts, the
prescription changes illustrated in this study would reduce toxicity in certain patients and
help push the prescription dose to the maximum tolerable value.
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The direction of the change in prescription (dose escalation versus dose deescalation) is dependent on several factors. First, the direction of the change in
prescription is dependent on the sample population used for the modeling study. Using a
complication probability of 22.6% the overall change in dose prescription was negative
(indicating a dose reduction) for our patient cohort (Table 17). However, when a reduced
patient cohort was used that excluded patients for whom initial clinical values exceeded
our dose limits, the changes in prescription were around 0, indicating that the positive and
negative changes cancelled out (Table 18). The overall change in prescription is also
dependent on the exact complication probability that is used. As the complication
probability is increased, the lung dose limit is relaxed, and we are able to increase the
prescription dose (Figure 33). These results suggest that if using the data in the current
study to design a clinical trial, the complication probability and study cohort will have to
be taken into account. The allowable complication probability is a clinical decision and
must consider the tumor control as well as the normal tissue toxicity. As with any new
technology or trial, a logical starting point to use (for the complication probability) is the
current existing paradigm in the clinic. Furthermore, each patient population will contain
patients whose clinical dose-volume parameters exceed the allowable limits because the
physician made a clinical decision to sacrifice normal tissue toxicity for tumor control.
We demonstrated the effect of these patients on the overall prescription dose change by
running a simulation where they were excluded from our analysis. In a clinical trial, one
way to account for these patients is to artificially increase the allowable complication
probability.
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The most frequent dose limiting organ observed was the lung, followed by the
spinal cord, esophagus, and the heart (Table 20). These results are in line with what has
been observed in the clinic. For thoracic treatment planning, the most frequent dose
limiting organ is often the lung, followed by either the spinal cord or the esophagus
depending on the location of the tumor. Our results demonstrated that as the allowable
lung complication probability is increased the lung limit is relaxed and therefore is a
limiting organ for fewer cases.
Van Baardwijk et al (49) performed a simulation study using 65 NSCLC patients
where a lung dose limit and a spinal cord limit were used to escalate the doses. Although,
the Van Baardwijk et al (49) study did not use genetic biomarkers (SNPs) in their dose
prescription scheme, it is pertinent to compare the results of the 2 studies. The Van
Baardwijk et al (49) used a nominal starting prescription of 60 Gy, a MLD limit of 19 Gy,
and a spinal cord limit of 54 Gy for each patient. They found that on average they could
increase the tumor dose by 6.6 Gy using a MLD limit of 19 Gy and a spinal cord limit of
54 Gy. The 6.6 Gy change in target dose is in line with our reported change of around 6
Gy (Table 17). However, it should be noted that we report a median change of 6 Gy
(either escalation or de-escalation) in target dose for the entire patient population, while
Van Baardwijk et al (49) report an average escalation in target dose of 6.6 Gy. The
differences can be attributed to several factors. The population studies used in our
simulation and the simulation provided by Van Baardwijk et al (49) are different. The
patients in our cohort received prescription doses ranging from 60 to 72 Gy, while all of
the patients in the Van Baardwijk et al (49) study started with nominal prescription doses
of 60 Gy. Furthermore, Van Baardwijk et al (49) used a population-based MLD limit of
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19 Gy while we used individualized MLD limits that are determined from a model that
incorporates biomarkers. Furthermore, our patient cohort contained patients for whom the
dose-volume metrics for the spinal cord, esophagus, and heart exceeded our set limit prior
to any escalation or de-escalation. Despite the differences in study design, both studies
illustrate in silico, that a change in dose to the target for lung cancer patients can be
achieved by prescribing doses that fully utilize the maximum allowable dose values to the
normal tissue organs. Our results and those presented by Van Baardwijk et al (49)
demonstrate the importance of performing simulation studies. Prior to conducting dose
personalization clinical trials, simulation studies are needed to demonstrate the potential
gain for the patient.
The current study uses a lung NTCP model to derive a personalized MLD limit
that is in turn used to determine a personalized dose prescription for each patient. As
modeling methods improve and more data is collected, it is possible that more patient and
clinical factors will be found to be associated with the risk of developing radiation
pneumonitis. In future work, these additional factors can be incorporated into the model
to further personalize the MLD limit and the prescription dose. Furthermore, the concept
of using a predictive model to determine a personalized dose limit can be extended to the
esophagus, spinal cord, and liver, as data for those organs are accumulated. In this study,
a predictive model was used exclusively to scale the prescription dose, in future work it
will be possible to use an NTCP model to help with treatment planning. For example, if it
is determined by the toxicity model that a patient can withstand a higher MLD, then dose
can be taken off another organ (the spinal cord for example) and pushed through the lung.
Furthermore, the model can be used to help decide which treatment modality to use for a
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patient. If the model-determined MLD limit cannot be achieved with 3D-CRT then the
toxicity model can provide further justification to use either IMRT or proton radiation
therapy. While the hypothesis that proton treatment plans provide more favorable DVHs
than photon treatment plans is still under investigation, for individual patients using a
different treatment modality may enable the model determined limit to be achieved. The
re-planning step was performed for 2 patients to illustrate the principle. The 2 patients
were treated with 3D-CRT and had MLDs of 19.48 and 28.48 Gy. The model-determined
limit was 17.81 Gy for the patient that received 19.48 Gy, and 26.16 Gy for the patient
that received 28.48 Gy. Under the original assumptions of the simulation the prescription
for these 2 patients would be lowered. However, experienced dosimetrists re-planned the
patients with IMRT and protons. The 3D-CRT, IMRT, and proton treatment plans for one
of patients are shown in Figure 34. Both the IMRT and protons plans results in MLDs
below the model-determined limit for both patients (Table 22). The provided example
illustrates that for certain patients, the personalized MLD limit may be achieved by replanning instead of lowering the prescription dose. The model-determined MLD limit can
be used in this manner to justify the use of more advanced modalities such as IMRT and
proton therapy.
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3D-CRT

IMRT

Protons
Figure 34: Example of a
patient that was replanned such that the
model-determined MLD
limit could be achieved.
Planes
of
dose
distributions are shown
for 3D-CRT, IMRT, and
protons for one patient.

3D – CRT
MLD

IMRT
MLD

Proton
MLD

MLD Limit

Patient 1

19.48

12.77

8.45

17.81

Patient 2

28.48

24.12

21.74

26.16

Table 22: Re-planning example for 2 patients. The 3D-CRT, IMRT and Proton
MLDs are shown. The model determined MLD limit is also displayed.
The work presented in this study is a proof of principle simulation and more work
is needed before the proper use of a toxicity model can be determined. The most
important work remaining is to verify the SNP results. Because of the large number of
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SNPs available for investigation, there is a high probability of finding a significant
association between SNPs and pneumonitis. In other words, when a large number of
SNPs are investigated, there is a high probability of finding false positives. Therefore,
work is underway to validate the SNPs in an independent patient cohort. It should be
noted that the SNPs used for the current study were not randomly selected but were
chosen because of their association with the inflammation process (38). Finally, it should
be noted that this study does not suggest that the proper use of this model is to replace the
current clinical paradigm. The model alone cannot be used to make clinical decision
about the dose to the tumor. The model does not replace common sense, the clinical
judgment of the physician, insurance considerations, or practical considerations.
However, we believe that the model can be used as a tool and guide to help physicians
make clinical decision. In our clinic, thoracic physicians implicitly (in some cases
explicitly) take into account factors such as concurrent chemotherapy, prior surgery, and
PFT data when deciding how much lung dose is safe to deliver. With increased data and
improved modeling methods more factors may be found to be predictive for toxicity, and
a model used in a manner described by the current study can aide physicians in making
clinical decisions about how much dose to deliver to the lung.
Conclusion
The current study presents a virtual proof of principle simulation trial where a
personalized model-determined lung dose limit was used to change the prescription dose.
It was determined that for individual patients the model generated prescription was
different than the clinically achieved prescription. The working hypothesis for this study
is accepted; the median change for an individual patient was 5.8 Gy. The magnitude and
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direction of the change was dependent on the selected complication probability.
Furthermore, we found that the model determined lung limit was the most frequent dose
limiting organ. As more factors are found to be associated with normal tissue toxicity, a
model used in the manner described by the current study can help physicians in
determining how much dose can safely be delivered to the tumor and normal tissues.
Conclusions
Study uncertainties
Uncertainties associated with each individual specific aim have been noted in
previous sections. For example, the uncertainty associated with calculating ventilation
images was investigated in specific aim 1, the uncertainty of using SNPs was noted in
specific aim 3, and the uncertainty of using the GTV centroid analysis was discussed in
specific aim 1. In addition to uncertainties associated with each specific aim there are
several modeling uncertainties that affect all dose-response modeling work. The biggest
overall limitation in the dose response modeling field is the toxicity scoring system. The
scoring system used for performing a toxicity modeling analysis is subjective. It is
subjective to the patient as well as the clinician. For example, one of the criteria for
scoring radiation pneumonitis is patient-reported symptoms. This is subjective because
certain patients may complain more than others or certain patients may have poor lung
conditions prior to beginning treatment and therefore don’t report changes in symptoms.
Another portion of the radiation pneumonitis scoring criteria is medical intervention. The
medical intervention criterion is subjective because some physicians may feel that
medical intervention is warranted in certain situations while other physicians may think
that no action is necessary. The subjectivity of the scoring system due to both the
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clinician and the patient adds uncertainty into the dose-response modeling process
because severe (grade 3-5) radiation pneumonitis was the end point for all of our analysis.
Another limitation to dose-response modeling is the sparse data that is available. The
number of patients developing severe toxicity is low, which is a positive outcome for the
patient. However, the low number of events (patients developing radiation pneumonitis)
hinders the statistical power of our modeling methods. Finally, in some cases the toxicity
reported may not be due to radiation therapy. Patients with NSCLC are often also
afflicted with other diseases such as COPD, emphysema, and heart disease. A number of
symptoms that may be perceived as being caused by radiation therapy can also be caused
by the patient’s prior existing conditions. In extreme conditions, even grade 5 toxicity
(death) may be difficult to identify because the patient’s death may be a result of nonradiation causes (such as tumor progression or pre-existing lung conditions).
The other important factor that adds uncertainty into thoracic dose-response
modeling is organ motion. Specifically, intra-fractional organ motion due to breathing
and inter-fractional organ motion due to set-up uncertainty can cause a deviation between
the intended and delivered dose distributions. Therefore, it is possible that the dose
distributions that were used for the dose-response analysis may not be a completely
accurate representation of the delivered doses. However, studies suggest that motion
causes the largest uncertainty in the dose calculations in heterogeneous dose regions (85)
and that motion minimally affects the accuracy of dose calculations to normal tissue when
evaluated using the DVH (86). Organ motion also causes uncertainty in the organ
contouring process. With the routine clinical use of 4DCT, multiple imaging datasets are
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available for contouring of the normal tissue organs. The image set chosen to contour the
organs of interest may affect the contour itself.
Conclusions
In specific aim 1 we used our large NSCLC patient database to investigate the
relationship between the spatial location of the deposited lung dose and severe radiation
pneumonitis. We performed the analysis using the GTV centroid as well as the entire 3D
dose distribution. It was determined that for our patient cohort the spatial location of the
dose does not influence the risk of radiation pneumonitis.
In specific aim 2 we investigated the utility of 4DCT-based ventilation imaging in
assessing lung injury. We first presented a unique dataset of mid-treatment weekly
calculated ventilation images. We did not find a consistent pattern of ventilation change
as a function of dose. However, we did find that ventilation and ventilation change was a
function of anatomy. Specifically, our results showed that pre-treatment ventilation
values were lower in lobes that contained the tumor, and if the tumor decreased in size,
the lobe was likely to re-inflate and ventilation would increase. Conversely, our results
showed that when there was no change in either the tumor or normal tissue anatomy,
there was no change in the ventilation distribution. The second portion of specific aim 2
incorporated pre-treatment ventilation images into a dose response model. Although there
were some promising results relating pre-treatment function (as measured by ventilation)
and severe radiation pneumonitis we were not able to significantly improve the fit of our
model using ventilation imaging. We believe more patients may be able to clarify the
relationship between dose to highly ventilated portions of the lung and radiation
pneumonitis.
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In specific aim 3 we performed a proof of principle virtual simulation study where
a personalized model-determined lung limit was used to scale the prescription dose. We
found that for individual patients, using the personalized model lung dose limit resulted in
a different prescription than what was achieved clinically for the patient. The median
difference between the model-generated prescription and the clinically achieved
prescription was 5.8 Gy. Our simulation results demonstrated the methodology and
preliminary data that could eventually be used to design a clinical trial. More work is
needed to verify the biomarkers used in our study, add additional factors into the
predictive model, and determine the proper use of the toxicity model within the treatment
design paradigm.
Clinical significance of research
The spatial study presented in this work adds a significant clinical contribution to
existing literature and clinical knowledge. Because of the size of our patient cohort and
the rigor of our modeling methods, we believe the current study provides an important
addition to the existing knowledge about the relationship between spatial location and
radiation pneumonitis. The spatial location within the lung is a pertinent clinical topic
because physicians need to know whether it is important to take the spatial location of the
tumor within the lung into account when considering how much dose can safely be
delivered to the healthy lung. Furthermore, the spatial methods presented in the current
work can be extended to other organs and other treatment modalities. For example, it may
be of interest whether or not toxicity is dependent on the spatial location of the dose
within the esophagus or liver. The methods used in this study can also be extended to
thoracic proton therapy.
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Although we did not find a statistically significant relationship between
ventilation-based functional information and radiation pneumonitis, specific aim 2
provided some promising clinical results. To our knowledge, the serial ventilation study
was the first study that has investigated the mid-treatment changes in ventilation. Midtreatment changes in ventilation may be useful for the clinician to assess. In theory, the
physician may take changes in lung function into account when deciding on whether or
not to adapt the radiation treatment plan. By incorporating pre-treatment ventilation data
into modeling we have provided an important step in using imaging to assess lung
function and predict toxicity. There has been a lot of recent interest in using imaging to
assess and predict for toxicity (40-43, 59-62). However, the results have been limited by
the number of patients enrolled in the studies and by the incomplete understanding and
assessment of lung function. In future work, lung function will be assessed by a
combination of imaging modalities (ventilation, perfusion, diffusion, and inflammation).
The ventilation results presented in this work may provide one of the important pieces
necessary to gain a complete understanding of lung function. This work was not only
important from a modeling aspect but from a 4DCT-based ventilation aspect as well.
There has been a lot of recent interest in 4DCT-based ventilation calculation
methodology and using 4DCT-based ventilation imaging to reduce dose to highly
ventilated portions of the lung. However, there has been no data to suggest using
ventilation imaging in treatment planning will reduce clinical toxicity. This is the first
study attempting to relate dose to ventilated portions of the lung and clinical symptoms.
Although we did not find a significant result, we show some promising data that can
provide the basis for future work relating dose, ventilation, and clinical symptoms.

116
In the virtual simulation trial, we have provided the methodology that can be used
to determine personalized lung dose limits and subsequently personalized prescription
doses. As mentioned in specific aim 3, this is something that thoracic physicians may
implicitly do already. When deciding how much dose can safely be delivered to the
healthy lung, physicians may take into account factors such as surgery status,
chemotherapy status, and PFT scores. As more factors are determined to be predictive of
radiation pneumonitis, using a model in the manner shown in Specific Aim 3 can be a
useful tool and guide for clinicians in determining a personalized lung dose limit and
subsequently a personalized prescription. More work is necessary before such a model
can be utilized in the clinic; however, the work done in Specific Aim 3 provides the
framework in which a model can be used to derive a personalized prescription dose.
Future Work
Future work relating to the specific studies is discussed within each specific aim.
For example, as more patients are gathered for the spatial study (specific aim 1) it would
be useful to perform the 3D spatial dose analysis for smaller cohorts of patients that are
grouped according to disease stage. For the ventilation study (both the serial ventilation
study and the pre-treatment ventilation study), more patients are needed. Furthermore, it
would be informative to investigate 4DCT-based ventilation images acquired several
weeks or months after the completion of therapy, since radiation damage (to the tumor
and normal tissue) occurs after the completion of therapy. For the virtual simulation
study, the next important step is to verify the SNP data. Another possible continuation of
the virtual trial is to include more factors (such as patient smoking status) that may be
predictive of radiation pneumonitis into the modeling simulation.
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There are a several different ways in which the current research can be extended.
One important area is the toxicity scoring system. As mentioned in previous section, the
toxicity scoring system for radiation pneumonitis is subjective to the patient as well as the
clinician. More work is needed to generate an objective toxicity scoring system. One
potential method involves the use of imaging as a surrogate for clinical symptoms.
However, since clinical symptoms are the important end point to the clinician, work is
needed relating imaging based scoring of radiation pneumonitis and symptom based
scoring of radiation pneumonitis.
Imaging can also be used to help identify early changes in lung function that can
predict for radiation pneumonitis. In the current study, we investigated ventilation based
changes; however, work is needed to get a complete understanding of lung function. In
future work, more information about lung function could be gained by combining
imaging modalities that assess different aspects of lung function.
It is also possible to extend the current modeling work to other treatment
modalities and other treatment sites. For example, the spatial analysis could be extended
to patients undergoing proton therapy. The modeling work can be applied to other organs
such as the brain, liver, and esophagus. Specifically, it would be informative to apply the
spatial work to the liver and esophagus and incorporate functional imaging into
predictions methods for the brain and liver.
There is also great potential to incorporate modeling work into hypo-fractionated
treatments. Because of their convenience and promising survival rates stereotactic body
radiotherapy (SBRT) has been increasing in popularity. However, relatively little is
known about thoracic toxicity associated with SBRT (6). More work is needed to relate
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basic dose-volume metrics and SBRT toxicity. Once a dose-volume relationship has been
established, further work incorporating spatial and functional information can be
performed. Another possibility is to apply this work to re-treatments. As survival rates
increase radiation re-treatments are becoming more common and as is the case with
SBRT, there is relatively little toxicity data for patients undergoing re-treatments. As data
is collected, the first step will be to establish a dose-volume relationship and then test for
other factors that may be predictive of toxicity.
Response to hypothesis
The purpose of this work was to incorporate spatial and functional information
into a predictive model and determine whether the fit of the model to the data could be
improved. In a strict sense, the hypothesis is rejected; we were not able to significantly
improve the model fit to the data. Specifically, incorporating spatial information and
ventilation-based functional information did not significantly improve the fit of the
model. Although the hypothesis was rejected the study had some important findings. We
did not find a correlation between the spatial location of the dose and radiation
pneumonitis. We found that ventilation and ventilation change was a function of the
changing thoracic anatomy. We presented some promising (although not statistically
significant) results relating pre-treatment ventilation and radiation pneumonitis. Finally,
we presented a simulation study where a personalized model-determined lung dose limit
was used to change the prescription dose. It was determined that for individual patients
the model generated prescription was different than the clinically achieved prescription.
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